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ABBREVIATIONS 
129  –  129S6/SvEv strain or, more generally, all 129 strains 
3-MT  –  3-methoxytyramine 
5-HIAA  –  5-hydroxyindoleacetic acid 
5-HT  –  5-hydroxytryptamine or serotonin 
5-HTP –  5-hydroxytryptophan 
AADC  –  aromatic amino acid decarboxylase 
AC – adenylate cyclase 
ANOVA  –  analysis of variance 
B6  –  C57BL/6 (strain; a substrain to C57) 
BNST  –  bed nucleus of the stria terminalis 
C57  –  C57BL strains 
CA1  –  cornu ammonis 1 of hippocampus 
CA3  –  cornu ammonis 3 of hippocampus 
cDNA  –  complementary DNA 
COMT  –  catechol-O-methyl transferase 
CPu  –  caudate nucleus and putamen (dorsal striatum) 
DA  –  dopamine 
DAT  –  DA transporter 
DBH  –  DA beta-hydroxylase 
D1  –  DA type 1 (receptor) 
D2  –  DA type 2 (receptor) 
D2Lh  –  long variant of the D2 receptor 
D2Sh  –  short variant of the D2 receptor 
EP  –  entopeduncular nucleus 
DIDMOAD  –  diabetes insipidus, diabetes mellitus, optic nerve atrophy, 
deafness 
Drd1  –  gene encoding the D1 receptor 
Drd2  –  gene encoding the D2 receptor 
DNA  –  deoxyribonucleic acid 
DOPAC  –  3,4-dihydroxyphenylacetic acid 
E  –  embryonic day 
ER  –  endoplasmic reticulum 
FST  –  forced swim test 
GABA  –  gamma-aminobutyric acid 
GABAA-R  –  GABA-A receptor 
GABA-T  –  GABA transaminase 
HPLC  –  high performance liquid chromatography 
Hprt1  –  hypoxanthine phosphoribosyltransferase 1 
HVA  –  homovanillic acid 
LacZNeo  –  beta-galactosidase/neomycin fusion gene 
LORR  –  loss of righting reflex 
MAO  –  monoamine oxidase 
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mRNA  –  messenger ribonucleic acid 
MSN  –  medium spiny neuron 
NA  –  noradrenaline 
NAT  –  NA transporter 
NMDA  –  N-methyl-D-aspartate receptor 
NMN  –  normetanephrine 
P  –  postnatal day 
qRT-PCR  –  quantitative real-time polymerase chain reaction 
SEM  –  standard error of the mean 
SERT  –  5-HT transporter 
siRNA  –  small interfering RNA 
SN  –  substantia nigra 
SNc  –  compact part of the substantia nigra 
SNr  –  reticular part of the substantia nigra 
SSADH  –  succinate-semialdehyde dehydrogenase 
SSRI  –  selective 5-HT reuptake inhibitor 
STN  –  subthalamic nucleus 
TCA  –  tricyclic antidepressant 
TPH  –  tryptophane hydroxylase 
TST  –  tail suspension test 
UPR  –  unfolded protein response 
VTA  –  ventral tegmental area 
Wfs1  –  Wolfram Syndrome 1 gene in species other than humans 
WFS1  –  Wolfram Syndrome 1 gene in humans 
Wfs1 –/–  –  homozygous mutants lacking both functional alleles of the 
Wfs1 gene 
Wfs1 +/–  –  heterozygous mutants having only one functional allele of the 
Wfs1 gene 
Wfs1 +/+  –  wild-type littermates of Wfs1-deficient mice 
WS  –  Wolfram syndrome  
3
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INTRODUCTION 
Wolframin (WFS1 protein) is transcribed from the WFS1 gene. It is an endo-
plasmic reticulum (ER) membrane protein important for preserving intracellular 
calcium homeostasis (Osman et al., 2003, Takei et al., 2006) and insulin 
secretion (Fonseca et al., 2012). Wfs1 is also essential for maintaining the 
unfolded protein response (UPR) in ER stress and lack of WFS1 leads to 
uncontrolled UPR and apoptosis (Fonseca et al., 2010). WFS1 expression has 
been detected in the heart, lung, liver, pancreas and brain. It seems that 
pancreatic beta cells and neurons are most vulnerable to WFS1 deficiency. In the 
pancreas, WFS1 is located to secretory granules of pancreatic β-cells (Hatanaka 
et al., 2011) and WFS1 deficiency leads to apoptosis of β-cells and diabetes 
(Fonseca et al., 2010). Homozygous mutations and some forms of compound 
heterozygosity in the WFS1 gene in humans cause Wolfram syndrome (WS), a 
very low prevalence disease (estimated 1/700 000 to 1/550 000), first described 
in 1938 by Wolfram and Wagener (Wolfram & Wagener, 1938, Inoue et al., 
1998, Strom et al., 1998, Cano et al., 2007). Starting in early adolescence, WS 
patients in addition to DIDMOAD (diabetes insipidus, mellitus, optic atrophy 
and deafness) have a high susceptibility to psychiatric disorders, such as 
depression, psychosis, impulsivity and aggression (Barrett et al., 1995, Swift et 
al., 1990, Swift et al., 1991, Swift & Swift, 2005). WFS1 heterozygotes have 26 
times higher psychiatric hospitalization primarily due to severe depression 
(Swift et al., 1998). WFS1 carriers have been shown to suffer from generalized 
anxiety and suicide attempts (Swift et al., 1998). It is also important to note that 
some WFS1 polymorphisms are associated with increased risk for mood 
disorders (Koido et al., 2005). 
These findings raise the question why the lack of wolframin results in 
psychiatric symptoms. Detailed Wfs1 expression has not been studied in the 
human brain, the most comprehensive research to date regarding the neuro-
anatomical localization of Wfs1 have been conducted in mice (Luuk et al., 
2008, Tekko et al., 2014). By looking at the ontogenetic expression of Wfs1, 
Tekko et al (2014) showed that wolframin is first detected in the mouse brain on 
embryonic day 15.5 in the central amygdala and caudate-putamen (CPu). Later, 
Wfs1 expression widens to encompass additional brain regions associated with 
the extended amygdala, limbic system and basal ganglia concepts, which 
constitute important brain networks responsible for experiencing emotions, 
anxiety, motivations and the smooth execution of movements (Luuk et al 2008). 
Luuk et al (2008) studied expression of wolframin protein in adult mouse brain, 
Wfs1-positive nerve fibers were detected in the substantia nigra (SN), ventral 
tegmental area (VTA) and medial forebrain bundle and Wfs1-positive neurons 
were shown in the nucleus accumbens and posterior CPu. Moreover, strong 
Wfs1 expression was found in the central amygdala and CA1 region of the 
hippocampus (Luuk et al., 2008). In support to the neuroanatomical findings, 
behavioral animal studies have associated Wfs1 to anxiety (Luuk et al., 2009, 
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Kesner et al., 2009, Koks et al., 2002) and also point to a role of Wfs1 in the 
dopaminergic system (Luuk et al., 2009). 
Together, the previous results lead us to suspect that alterations in mono-
aminergic (dopamine – DA, serotonin – 5-HT, noradrenaline – NA) and 
gamma-aminobutyric (GABA-ergic) systems are responsible for the symptoms 
seen in Wfs1 deficiency. Monoamines are known to be involved in a wide range 
of brain functions and disturbances in these systems lead to various neurologic 
and psychiatric conditions. For example low striatal DA levels due to loss of 
DA-ergic neurons in the compact part of the SN cause serious motor system 
deficiencies in the form of Parkinson's disease. Higher levels of depression 
(around 40%), likely caused by loss of DA and NA neurons, are also seen in 
Parkinson’s patients (Cummings, 1992, Cummings & Masterman, 1999, Remy 
et al., 2005). Some DA agonists are effective antidepressants (Willner, 1997). 
By contrast, pathologically elevated DA signaling in DA pathways is 
considered the cause for psychotic disorders and is treated with DA receptor 
antagonists (Howes & Kapur, 2009). Lower levels of central 5-HT are found in 
patients with mood disorders (Edwards & Anderson, 1999). Similarly, drugs 
elevating brain 5-HT and NA levels are effective antidepressants. Therefore, 
monoamine systems are the main drug targets in mood disorders. GABA is the 
main inhibitory neurotransmitter in the brain and, specifically, GABA receptor 
A (GABAA-R) subtypes have been implicated in anxiety, since they are the 
molecular target for benzodiazepines which are highly effective anxiolytic 
agonists of these receptors (Petroff, 2002, Hines et al., 2012). 
The aim of this dissertation was to psychopharmacologically study the 
monoaminergic and GABA-ergic systems in Wfs1-deficient mice in order to 
detect accompanying biochemical alterations in the brain and assess this mouse 
strain as a potential model for depressive and anxiety disorders. For this, we 
used Wfs1-deficient mice that are missing exon 8 in the Wfs1 gene (Luuk et al., 
2009). It is the largest exon of the Wfs1 gene and in WS has the majority of the 
mutations (Khanim et al., 2001). Replacement of this exon with a LacZ cassette 
did not abolish wolframin production, but rendered the protein dysfunctional. In 
the first paper, several methods were utilized to measure various aspects of the 
DA-ergic system in Wfs1-deficient mice after administration of either direct or 
indirect DA agonists. The second paper concerns 5-HT-ergic and NA-ergic 
signaling where emphasis was put on behavioral despair methods, which are 
sensitive to 5-HT-ergic and NA-ergic antidepressants. In the third paper, 
GABA-related behavior was studied along with the expression of GABAA 
receptor subtype encoding genes in response alcohol administration. 
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REVIEW OF LITERATURE 
1. Characterization of the WFS1 gene and protein 
Wolfram syndrome 1 (WFS1) gene is located on chromosome 4p16.1 in 
humans and 5qB3 in mice (Inoue et al., 1998, Strom et al., 1998). Wfs1 gene 
has 8 exons and spans approximately 33.4 kb of genomic DNA. Wfs1 gene 
code is used to generate the Wfs1 protein, wolframin. Translation of wolframin 
starts from the second exon. Wolframin is an endoglycosidase H-sensitive 
endoplasmic reticulum (ER) membrane glycoprotein, which consists of 890 
amino acids and weighs approximately 100 kDa (Takeda et al., 2001). The 
carboxy-terminal domain is in the ER lumen and the amino-terminal lumen lies 
in the cytoplasm (Hofmann et al., 2003, Inoue et al., 1998, Strom et al., 1998). 
Wolframin is a hydrophobic and tetrameric protein with 9 transmembrane 
segments (Hofmann et al., 2003, Rigoli et al., 2011). Presence of wolframin in 
the ER suggests roles in membrane protein biosynthesis and modification 
(Yamaguchi et al., 2004, Yamada et al., 2006, Zatyka et al., 2008). Wolframin 
has been found to participate in calcium homeostasis (Osman et al., 2003) and 
protect against ER stress response, since lack of Wfs1 leads to UPR and cell 
death (Fonseca et al., 2010). Strong expression of wolframin is found in 
pancreatic beta cells (Hofmann et al., 2003, Fonseca et al., 2010) and loss of 
wolframin leads to apoptosis and progressive beta cell loss (Ishihara et al., 
2004, Riggs et al., 2005, Yamada et al., 2006). 
WFS1 can be found in multiple tissues, but the precise localization has not 
been established for most organs. According to the Human Protein Atlas 
(www.proteinatlas.org), highest levels of WFS1 RNA are found in the cerebral 
cortex, lung, heart muscle, thyroid gland, spleen, adipose tissue, smooth muscle, 
ovaries, fallopian tubes, endometrium, prostate, testis, and urinary bladder. 
Expression of wolframin protein is strongest in the brain, pancreas, kidney, 
testis, placenta and parathyroid gland (Human Protein Atlas). Similarly, strong 
expression levels of Wfs1 protein in the mouse are found in the brain and heart, 
intermediate levels are found in the pancreas, skeletal muscle and liver and low 
amount is detected in the kidney and spleen (Hofmann et al., 2003). 
 
 
2. Wolfram syndrome and  
WFS1 mutations in psychiatric disorders 
Homozygous mutations and some forms of compound heterozygosity in the 
WFS1 gene cause Wolfram syndrome (WS, OMIM 222300), an autosomal 
recessive disorder characterized by diabetes insipidus, juvenile-onset non-
autoimmune diabetes mellitus, optic atrophy and deafness (Inoue et al., 1998, 
Strom et al., 1998, Cano et al., 2007). Individuals display variability in the 
clinical manifestations of WS, but the minimal diagnostic signs are considered 
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early onset diabetes mellitus and optic atrophy (83 percent of cases) (Barrett 
et al., 1995). WS has also been associated to deafness, urinary tract atony, 
gastrointestinal disorders (dysmotility), hydronephrosis, primary gonadal 
atrophy in males, mental retardation, neuropathy, epilepsy, glaucoma, cerebellar 
ataxia, nystagmus, dysphagia and sleep apnea (Swift et al., 1990, Swift et al., 
1991, Bitoun, 1994, Barrett et al., 1995, Minton et al., 2003, Chaussenot et al., 
2011). It has been found that the prevalence of WS is 1 in 100,000 in a North 
American population and 1 in 770,000 in the UK (Fraser & Gunn, 1977, Barrett 
et al., 1995). The prevalence of WS carriers is 0.28% in the United Kingdom 
and 1% in the United States (Barrett et al., 1995, Swift et al., 1991). 
WS is a progressive degenerative disease. Degeneration has been shown to 
start in early childhood with profound cerebellar and brainstem alterations and 
is fully evident by the age of 15 (Chaussenot et al., 2011, Hershey et al., 2012). 
Imaging studies suggest atrophy in the brainstem, cerebellum, optic nerve, 
hypothalamus and hippocampus (Leiva-Santana et al., 1993, Galluzzi et al., 
1999, Shannon et al., 1999, Hadidy et al., 2004). WS patients have a mean life 
expectancy of 30 years and usually die of neurological complications (central 
respiratory failure caused by brainstem atrophy) and kidney failure (result of 
urinary tract atony) (Barrett et al., 1995, Kinsley et al., 1995). 
It has been found that around 60% of WS patients manifest psychiatric 
symptoms such as depression, psychosis, impulsivity, and aggression (Swift et 
al., 1990). A recent study by Bischoff et al. (2015) found that individuals with 
genetically confirmed WFS had no impairment in cognitive functions or self-
reported psychiatric domain whereas by the clinical evidence these people did 
have psychiatric problems mainly in the form of anxiety and hypersomnolence. 
Heterozygous carriers of WFS1 mutations have increased psychiatric 
hospitalization mainly due to depression (Swift & Swift, 2005). It has therefore 
been suggested that mutations in the WFS1 gene play a key role in the 
susceptibility to mood disorders (Swift et al., 1998, Koido et al., 2005, Swift & 
Swift, 2005). Animal studies support the role of Wfs1 in psychiatric symptoms 
(Koks et al., 2002, Luuk et al., 2009, Kesner et al., 2009). Although WFS1 
mutations are prevalent in many clinically important emotional and neurologic 
disorders, WFS1 has not been mapped in the human brain. Instead, thorough 
expression studies of Wfs1 have been conducted in the mouse brain (Luuk et 
al., 2008, Tekko et al., 2014). 
 
 
3. Neuroanatomical localization of Wfs1 
Developmentally, Wfs1 expression in the mouse forebrain first appears in the 
posterior CPu (dorsal striatum) and central amygdala from embryonic (E) day 
15.5 (Tekko et al., 2014). At the same time, weak Wfs1 expression is detected 
in the medial CPu. At E18.5 the signal becomes stronger also in the anterior 
part of the CPu. In the ventral striatum (nucleus accumbens), Wfs1 expression 
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appears at E16.5 and reaches its adult level at approximately postnatal (P) day 
20 (Tekko et al., 2014). Additionally, Wfs1 expression becomes detectable in 
many other brain nuclei, eg the cornu ammonis (CA) and subiculum regions of 
the hippocampus at E18.5, which show remarkable increase in Wfs1 expression 
immediately after birth at P0. At P2 expression still encompassed the whole CA 
region including the subiculum and dentate gyrus. However, selective CA1 
expression is achieved in the subsequent days while the CA3, subiculum and 
dentate gyrus expression faded. At P20, the adult (P60) level of Wfs1 
expression selectively in the CA1 and parasubiculum was reached (Tekko et al., 
2014). 
In the adult mouse brain, strong Wfs1 expression remains in the posterior 
caudate nucleus and capsular division of the central amygdaloid nucleus, being 
expressed also in the nucleus accumbens, dorsal part of the lateral bed nucleus 
of stria terminalis (BNST) and CA1 pyramidal cell layer region of the 
hippocampus (Luuk et al., 2008). In the midbrain, Wfs1-positive fibers are 
found in the reticular SN (Luuk et al., 2008). These fibers are most dense in the 
dorsomedial and dorsolateral reticular SN. Low levels of Wfs1-positive fibers 
are also detectable in the compact part of SN (Luuk et al., 2008). 
The expression pattern of Wfs1 in the mouse brain corresponds to the limbic 
system, extended amygdala and basal ganglia concepts. These systems are 
connected to each other and some of their regions are overlapping. The limbic 
system is composed of different subcortical nuclei responsible for the regulation 
and experience of anxiety, emotions, motivation, and formation of long-term 
memories (Rolls, 2015). It consists of the amygdala, hippocampus, anterior 
nuclei of thalamus, fornix, mammillary bodies, septum pellucidum, cingulate 
gyrus, parahippocampal gyrus, and midbrain limbic areas although the concept 
of a single limbic system seems to be outmoded (Rolls, 2015). The Wfs1-rich 
central amygdaloid nucleus is considered a crucial region for experiencing fear 
(Kalin et al., 2004). The extended amygdala with the BNST mediates fear, 
anxiety and reward (Jennings et al., 2013) and is connected to the VTA. For 
example, photostimulation of gamma-aminobutyric (GABA-ergic) projections 
of the BNST result in rewarding and anxiolytic behavior. In vivo 
photostimulation of BNST glutamatergic projections to the VTA induce 
anxiogenic behavior (Jennings et al., 2013). 
The basal ganglia are collection of subcortical nuclei responsible for reward 
behavior and the execution of skilled movements. They are made up of the 
caudate nucleus, nucleus accumbens, putamen, subthalamic nucleus (STN), 
globus pallidus (GP) and SN. The varied roles of the basal ganglia become 
evident from the pathologies, which stem from damage and metabolic 
alterations to these regions, such as hemiballismus, dystonia, addiction to 
psychoactive drugs, Parkinson's disease and Huntington's disease (Albin et al., 
1989).  
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4. Wfs1-deficient mice as models of WS and 
emotional disorders 
In order to elucidate the function of Wfs1, multiple Wfs1-deficient mouse lines 
have been generated by using different strategies (Ishihara et al., 2004, Riggs et 
al., 2005, Luuk et al., 2009). Riggs et al 2005 made a conditional beta-cell 
specific knock-out mouse line (129 SVJ background) targeting Wfs1 exon 8 
that showed impaired glucose-stimulated insulin secretion, asymmetry and 
disruption of islet architecture without loss of beta cell mass at 12 weeks of age. 
At 24 weeks of age, reduction in beta cell mass was observed along with overt 
diabetes (Riggs et al., 2005). Homozygous Wfs1-deficient mice also had a 
significantly lower body mass at six months. 
Ishihara et al made a full knock-out by deleting the second exon of the Wfs1 
gene. These mice, in a 129/SVEV x C57BL6 F2 background, generally 
displayed a similar diabetic phenotype (decreased insulin secretion in the 
glucose tolerance test and increased glucose levels) as in Wfs1-deficient made 
by Riggs et al (2005). It became evident that in a C57 background, diabetes did 
not develop. Kato et al (2008) studied the behavior of mice in a B6 background 
and found few differences between the Wfs1-deficient homozygotes and wild-
type mice. The mutant animals have significantly shorter escape latency in 
passive and active avoidance tests and increased freezing in the training phase 
of the fear conditioning test (Kato et al., 2008). 
Mice used in this study were F2 hybrids [(129S6/SvEvTac × C57BL/6) × 
(129S6/SvEvTac × C57BL/6)]. Young adult mutant animals (2–3 months) in 
this background have glucose intolerance, although the baseline levels of blood 
glucose of Wfs1-deficient mice are not different from their wild-type littermates 
(Raud et al., 2009). The mice display significantly more anxiety-like behavior 
in the elevated plus maze test and are more responsive to the GABAA-R agonist 
diazepam (Luuk et al., 2009). Wfs1-deficient homozygous animals also 
exhibited a three-fold increase in plasma corticosterone levels (Luuk et al., 
2009). Interestingly, the homozygous Wfs1-deficient mice display characteristic 
vocalizations when under stress-inducing conditions (Luuk et al 2009). 
Injections of the direct DA agonist apomorphine caused a stronger motor 
response whereas the indirect agonist amphetamine induced significantly less 
motor stimulation in Wfs1-deficient mice (Luuk et al., 2009). 
In summary, findings from clinical research conducted on humans, along 
with neuroanatomical and preliminary psychopharmacological studies of Wfs1-
deficient mice point to the fact that Wfs1-deficiency may lead to disturbances in 
central monoamine and GABA systems. 
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5. Etiologies of emotional disorders 
5.1. Monoamine hypothesis 
Central monoamines are a group of neurotransmitters, which participate in 
mediating a wide range of brain functions. Monoamines derive from aromatic 
aminoacids tyrosine, phenylalanine and tryptophan. They are categorized into two 
groups, the catecholamines DA, adrenaline and NA, and the indoleamine 5-HT. 
According to the monoamine hypothesis, mood disorders are caused by a 
functional deficiency of monoamines, mostly NA-ergic and/or 5-HT-ergic 
(Hirschfeld, 2000). It has become clear that DA is also involved in regulating 
mood (Dailly et al., 2004). Therefore, monoamines are targeted by drugs used 
for treating mood disorders, although these drugs can be effective also when 
treating anxiety (Zohar & Westenberg, 2000). 
  
5.1.1. Dopamine 
5.1.1.1 Dopamine pathways of behavior and emotion regulation 
DA is a neurotransmitter implicated in many different brain functions and 
clinical disorders. Three of the DA pathways (nigrostriatal, mesolimbic, and 
mesocortical) have their cell bodies in the ventral midbrain and one, the 
tuberoinfundibular pathway, in the hypothalamus. The nigrostriatal and 
mesolimbic systems dominate in behavior and emotional regulation.  
The nigrostriatal DA pathway is important in the control of movement. 
Alterations in DA neurotransmission in this pathway thus usually result in either 
in the lack of (Parkinson's disease) or exaggerated movements. DA agonists 
elevate DA neurotransmission in the nigrostriatal pathway to increase 
behavioral activation in mice.  
Cell bodies of the nigrostriatal neurons lie in the compact part of the SN and 
their axon terminals are situated in the CPu, forming the presynaptic DA 
neurons (Anden et al., 1964). DA-ergic neurons make synapses with the 
postsynaptic GABA-ergic medium spiny neurons (MSN), which express two 
different receptor types, the DA D1-like (D1 and D5) and the DA D2-like (D2, 
D3, D4) receptors with the exception of presynaptic D2 autoreceptors. The D1 
receptor subtypes activate adenylate cyclase (AC), and the D2 subtypes inhibit 
AC (Missale et al., 1998). D1 receptors, encoded by the Drd1 gene, are only 
postsynaptically expressed. The D1-like receptors are primarily expressed in the 
direct pathway of movement originating from the basal ganglia. The direct 
pathway (also called striato-nigral/striato-entopenduncular) is composed of 
GABA-ergic neurons, which send axons to entopenduncular nucleus (EP) and 
to the reticular SN.  
The D2-like receptors are situated both pre- and postsynaptically (Khan et 
al., 1998). These two sites have different isoforms of the D2 receptor protein, 
which are encoded by the same gene (Drd2) but are the result of alternative 
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splicing. The presynaptic D2 receptors are of the short form (D2Sh) and the 
postsynaptic variant is of the long form (D2Lh). Presynaptic D2 neurons are 
autoinhibitory and act to antagonize DA release (Bowyer and Weiner, 1987, 
Mercuri et al., 1997) and lower excitability at axon terminals (Bunney et al., 
1973, Tepper et al., 1984). Blockage of D2 autoreceptors augments DA release 
(Fasano et al., 2008). The postsynaptic D2 receptors are expressed in the 
indirect DA pathway. The indirect pathway, otherwise known as the striato-
pallidal pathway, sends projections to the STN. From the STN, glutamatergic 
neurons are sent to the EP and SNr. 
The dorsal striatum is also innervated by other neurotransmitter systems, 
which modulate DA-ergic transmission. For example 5-HT (from raphe nuclei) 
and NA (from locus coeruleus and lateral tegmental area) neurons give rise to 
projections ending in the striatum (Mori et al., 1985). It has been shown that 5-HT 
binding to the 5-HT2C receptors can inhibit DA release in the striatum (Alex et 
al., 2005). 
The mesolimbic DA pathway is considered the most important reward 
pathway in the brain (Robison & Nestler, 2011). It is also strongly implicated in 
schizophrenia and depression (Heimer et al., 1997, Epstein et al., 1999, Malone 
et al., 2009). Changes related to drug addiction occur mainly in this pathway. 
Neuronal bodies of the mesolimbic system originate in the VTA and their axons 
traverse the lateral hypothalamus to innervate the nucleus accumbens (ventral 
striatum) in the basal forebrain. As in the dorsal striatum, the ventral striatum 
consists mostly of GABA-ergic MSN-s which are postsynaptic and express 
either D1 or D2 receptors (Robison & Nestler, 2011). The nucleus accumbens 
has efferents to multiple brain regions, eg to the ventral pallidum, lateral 
hypothalamus, SN, VTA, lateral hypothalamus, CPu, the BNST, septum, 
preoptic area, lateral habenula, lateral septum, retrorubral nucleus and central 
gray (Nauta et al., 1978, Groenewegen & Russchen, 1984, Usuda et al., 1998). 
 
5.1.1.2 Dopamine metabolism and pharmacology 
Dopamine is synthesized in two steps. First, L-tyrosine is hydroxylated by 
tyrosine hydroxylase to DOPA. Then, DOPA is decarboxylated to DA by 
aromatic amino acid decarboxylase (AADC) (Meiser et al., 2013). DA is 
metabolized to 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid 
(DOPAC), and homovanillic acid (HVA). These reactions are carried out by 
monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT). 
Physiologically, synaptic DA levels are set by tonic and phasic firing of 
midbrain DA neurons (Grace, 1991, Wanat et al., 2009). Greater levels of DA 
can be achieved by administering drugs acting as DA releasers. Two classes of 
DA agonist drugs are used to achieve motor activation, the direct DA agonists 
(eg apomorphine), which act on DA receptors to produce an effect similar to 
DA binding to its receptors and the indirect DA agonists (eg amphetamine), 
which enhance DA release by reversing the direction of the pumping 
5
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mechanism of the presynaptically located DA transporter (DAT) (Millan et al., 
2002, Vaughan & Foster, 2013). The DAT protein is physiologically 
responsible for the uptake or clearance of excess DA from the synaptic cleft 
(Vaughan & Foster, 2013). Strong expression of DAT is found on DA-ergic 
terminals in the dorsal and ventral striatum. 
One dose or many administrations of a dose of amphetamine in rodents 
causes an augmented psychomotor response or sensitization which can last 
several weeks. The mechanism underlying sensitization is under debate but it 
has been found to reverse, for example, insulin deficiency-induced reduction in 
sensitivity to amphetamine (Owens et al 2012). 
 
5.1.2. Serotonin and noradrenaline 
5-HT synthesis happens in two steps. The amino acid L-tryptophan is converted 
by tryptophan hydroxylase (TPH) to 5-hydroxytryptophan (5-HTP). Then, 5-HTP 
is decarboxylated by AADC to form 5-HT. By contrast, NA is synthesized from 
DA by DA beta-hydroxylase (DBH). The main metabolite of 5-HT is 5-HIAA 
(synthesized by MAO) and the metabolite of NA is normetanephrine (NMN) 
(synthesized by COMT). 
Depending on their mechanisms of action, different classes of 5-HT-ergic 
antidepressants are known. The SSRI-s (eg paroxetine) act specifically on the 5-
HT-ergic system by blocking the 5-HT transporter (SERT), the main molecule 
responsible for clearing 5-HT from the synaptic cleft (Murphy et al., 2004). 
Therefore, the SSRI-s raise serotonin levels and consequently produce an anti-
depressive effect. 5-HT is also important in the stress response (Chaouloff et al., 
1999). Currently, 7 families of 5-HT receptors, which mediate both excitatory 
and inhibitory transmission, are known. They are designated 5-HT1-5-HT7 
(Frazer & Hensler, 1999). All but the 5-HT3 are G-protein coupled receptors 
that activate intracellular messengers. 5-HT3 receptor is a ligand-gated ion 
channel. 5-HT neuron bodies lie in the raphe nuclei which are in 9 clusters and 
located in the midbrain, pons and medulla. 5-HT-ergic neurons innervate, 
among others, the spinal cord, SN, hypothalamus, amygdala, septum, neocortex, 
hippocampus, striatum and habenula.  
It has been found that tricyclic antidepressants (TCA-s) (eg imipramine) also 
target NA system in the brain. The TCA-s increase 5-HT and NA levels by 
blocking monoamine transporters with almost 4 times higher affinity of 
imipramine to NAT compared to SERT (Shank et al., 1988, Bolden-Watson & 
Richelson, 1993, Owens et al., 1997, Richelson, 2001). NA is involved in a 
variety of neurophysiologic processes and has for a long time been a target for 
antidepressive drugs in the treatment of mood disorders. NA-ergic neurons 
originate in the locus coeruleus and lateral tegmental area, innervating a large 
number of different brain areas (Racagni & Brunello, 1999). Key areas 
innervated by NA-ergic neurons are the amygdala, cingulate, gyrus, hippo-
campus, hypothalamus, cortex, striatum, and thalamus. 
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5.2. Gamma-aminobutyric system 
GABA is the main inhibitory neurotransmitter in the brain and spinal cord, 
present in up to 44% of all neurons and distributed over most brain areas. 
GABA can, due to the ubiquitous presence, influence practically all aspects of 
brain function. GABA is formed from glutamate by glutamic acid de-
carboxylase (GAD) and is metabolized to succinate by GABA transaminase 
(GABA-T) and succinic semialdehyde dehydrogenase (SSADH) (Petroff, 
2002). 
There are two general classes of GABA receptors (GABA-R-s) - GABAA 
and GABAB. GABAA-R-s are heteropentameric ligand-gated ion channels and 
GABAB-R-s are G protein-coupled metabotropic receptors. GABAA receptor is 
the main mediator of inhibitory neurotransmission in the brain and also the 
target of multiple drugs, such as anxiolytics, anticonvulsants, the sedative 
hypnotic benzodiazepines and alcohol. Pharmacologically, anxiety is generally 
treated with drugs that are GABAA-R agonists. A widely used anxiolytic drug is 
diazepam. At least 15 subunits of the GABAA-R are known and they show great 
heterogeneity in distribution (Fritschy & Mohler 1995). When molecules bind 
with the extracellular part of GABAA-R, a chloride-specific pore is opened. This 
hyperpolarizes the cell, thus inhibiting further action potentials (Petroff, 2002). 
The role of GABAA-R in anxiety is known, but it is under debate which of 
the GABAA-R subtypes mediate this action. There are four GABAA-R subtypes 
which are sensitive to anxiolytics, named α1, α2, α3, or α5. The α2 is more 
expressed in the limbic system and α3 in the reticular formation; accordingly, 
studies tend to show that the α2 subunit is responsible for the anxiolytic effect 
of diazepam in animals (Low et al., 2000).  
  
 
6. Concluding remarks 
It is evident that mutations in the gene encoding wolframin protein result in 
emotional disorders. First, data from human studies suggest that mutations in 
WFS1 have a role in anxiety and mood disorders. Second, although no data 
exists on the neuroanatomical localization of WFS1 in the human brain, studies 
of the mouse brain have located Wfs1 in regions involved in reward, movement, 
emotions and anxiety – functions, which are largely mediated by monoamine 
and GABA neurotransmitters. Third, psychopharmacological results have 
shown a possible DA release deficit and increased anxiety. 
Therefore, the aim of this dissertation was to study the GABA-ergic and 
monoaminergic systems in a Wfs1-deficient mouse line by using behavioral, 
biochemical and genetic methods. We hypothesize that Wfs1 deficiency in mice 
induces behavioral symptoms reflective of human emotional disorders and 
biochemical alterations to associated neurotransmitter systems. 
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AIMS OF THE STUDY 
According to the above presented analysis of literature the present dissertation 
aims to answer to the following questions:  
 
Dopamine 
1. Does Wfs1-deficiency induce behavioral symptoms indicative of a DA-ergic 
deficiency? 
2. How is DA metabolism affected by Wfs1 deficiency? 
 
Serotonin and noradrenaline 
1. Do the Wfs1-deficient mice display behavioral despair symptoms, reflective 
of depression, and altered behavioral response to SSRI-s and TCA-s?  
2. Are there biochemical differences to striatal 5-HT and NA systems between 
Wfs1-deficient and wild-type animals in response to a stressful open field 
exposure? 
 
Gamma-aminobutyric acid 
1. How does ethanol administration affect the anxiety-like phenotype of Wfs1-
deficient mice? 
2. Does Wfs1 deficiency in mice cause differences to ethanol-induced 
expression of genes encoding the GABAA receptor subunits? 
 
In general 
Does this Wfs1-deficient mouse model represent a usable choice when 
screening anxiolytic and antidepressant drugs and testing novel drug 
administration schemes in the treatment of WS?  
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MATERIALS AND METHODS 
1. Animals (Papers I, II, III) 
The majority of the mutations inducing Wolfram syndrome occur in exon 8 
(Cano et al., 2007, Hansen et al., 2005, Hardy et al., 1999). To mimic the 
human condition in the Wfs1-deficient mouse model the 8th exon was disrupted 
(Luuk et al., 2008). Breeding and genotyping were conducted in the Department 
of Physiology, University of Tartu. The papers were based on studies on young 
adult (age 2–4 months) male and female Wfs1-deficient mice. According to our 
previous data the animals at this age range do not display elevated basal glucose 
levels, i.e. they do not have overt diabetes (Luuk et al., 2009) However, they do 
have impaired response in the glucose tolerance test. We used F2 hybrids 
[(129S6/SvEvTac × C57BL/6) × (129S6/SvEvTac × C57BL/6)] for the experi-
ments, because the congenic footprint effect does not allow a pure background 
by backcrossing. It has been argued that a robust behavioral phenotype, caused 
by a mixed genetic background, obviates the need for back-crosses (Schalkwyk 
et al., 2007). All the genotypes (wild-type, heterozygous and homozygous 
Wfs1-deficient) were housed in their respective home cages. The mice were 
housed in groups of eight under a 12 hour light/dark cycle with lights on at 
7:00 a.m. The behavioral studies were performed between 9:00 a.m. and 6:00 
p.m. In the studies only littermates were used and compared. This approach was 
applied to overcome the possible extensive variability coming from the random 
background of F2 hybrids. All genotypes were represented by an equal or close 
to equal number of animals. Heterozygous animals were not used in the western 
blotting experiment in paper I and in the gene expression study in paper III. The 
number of mice used in each experiment is given under the corresponding 
figure and table. The animals had free access to food and water except during 
testing. In papers I and II, naive batches of mice were used for each experiment. 
 In paper III, the first batch of mice was used for the elevated plus-maze test 
and 7 days later for the locomotor activity test. The second batch of mice was 
used for the righting reflex test. To reduce the number of animals, mice 
receiving ethanol in the righting reflex test were used after a washout period of 
7 days for measuring the sedative/ hypnotic effect of pentobarbital and 
ketamine. The third batch of mice was used for the rotarod test. For ethanol 
metabolism studies and gene expression studies, the fourth and fifth batches of 
mice were used, respectively. Wfs1-deficient mice were always used in parallel 
with wild-type and heterozygous mice and the animals were randomly divided 
into the experimental groups. 
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2. Drugs (I, II, III) 
In paper I, amphetamine (amphetamine sulfate, Sigma-Aldrich, St Louis, MO, 
USA), an indirect agonist of DA, was injected intraperitoneally (i.p.) 30 min 
prior to testing. Apomorphine (apomorphine hydrochloride, Sigma-Aldrich, St 
Louis, MO, USA), a direct DA receptor agonist, was given subcutaneously 
(s.c.) 15 min before the experiment. Both compounds were diluted in 0.9% 
NaCl (B. Braun Melsungen AG, Germany). In the experiments measuring the 
stimulation of locomotor activity and DA metabolism, we used 5 mg/kg of 
amphetamine and 3 mg/kg of apomorphine. The mentioned doses of drugs were 
selected according to preliminary experiments where 5 mg/kg of amphetamine 
and 3 mg/kg of apomorphine caused a statistically significant increase in the 
locomotor activity of mice (Luuk et al., 2009). In the sensitization study, 
animals were treated with 2.5 mg/kg of amphetamine. This is a sub-threshold 
dose of amphetamine because it did not cause behavioral stereotypy or 
locomotor activation if given as a single dose (Luuk et al., 2009). 
In paper II, control group animals in the TST and FST received an injection 
of saline (0.9% NaCl solution) (B. Braun Melsungen AG, Germany). Imipramine 
hydrochloride and paroxetine hydrochloride hemihydrate (both purchased from 
Sigma-Aldrich, St Louis, MO, USA) were dissolved in saline. Imipramine was 
administered at doses of 10, 20 and 30 mg/kg and paroxetine at doses of 5, 10, 
20 and 30 mg/kg. All drugs were injected at a volume of 100 µl / 10 g 40 minutes 
before using the animal in the TST or FST. Effect of paroxetine was studied only 
in TST since this test was more sensitive for establishing the antidepressant-like 
effect of drugs compared to FST (Liu and Gershenfeld, 2001). 
In paper III, three doses of ethanol (0.5, 1 and 2 g/kg) were used in the 
elevated plus-maze and locomotor activity tests. In the rotarod test, only ethanol 
at the dose of 2 g/kg was used. Ethanol [5% (v/v) for 0.5 and 1 g/kg or 20% 
(v/v) for 2 g/kg] was injected 20 min prior to testing. In the LORR test, ethanol 
(4 g/kg), pentobarbital sodium salt (Sigma/Aldrich, 45 mg/kg) and ketamine 
hydrochloride (Vetoquinol Biowet Sp. Z.o.o., 150 mg/kg) were used. For the 
study of ethanol metabolism, mice received ethanol [2 or 4 g/kg 20% (v/v)] 
30 min before blood concentration measurements. For gene expression studies, 
animals were injected with ethanol (2 g/kg) 30 or 60 min before decapitation. 
All agents were diluted in 0.9% NaCl solution (B. Braun Melsungen AG, 
Germany) and injected intraperitoneally at a volume of 100 ml/10 g. 
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3. Behavioral experiments (I, II, III) 
3.1. Locomotor activity tests (I, II, III) 
3.1.1. Administration of amphetamine and apomorphine (I) 
In paper I, locomotor activity of mice was automatically registered for 30 min 
in photoelectric plexiglas motility boxes (448 mm × 448 mm × 450 mm, TSE, 
Technical and Scientific Equipment GmBH, Germany). The distance travelled, 
time in locomotion and number of corner entries were registered. Illumination 
level in the motility boxes during the experiments was approximately 400 lux. 
The higher illumination level was used to suppress spontaneous locomotor 
activity in mice. This approach enables one to see the motor stimulation at 
lower doses of DA agonists, otherwise being masked with a high exploratory 
activity of animals. The floors of motility boxes were cleaned thoroughly with 
5% alcohol and dried after each animal. In the beginning, animals were 
habituated (30 min) to the motility boxes on two consecutive days. This was 
done in order to reduce any behavioral activation due to novelty seeking. 
Thereafter the animals were tested in the same boxes with saline and drugs 
(amphetamine 5 mg/kg, apomorphine 3 mg/kg). 
Immediately after the behavioral testing, animals were taken to another room 
and decapitated for brain tissue dissection (for further details see paragraph 4 of 
Materials and methods). Since the behavioral experiments lasted 9 h, pre-
cautions were taken to control the possible daily fluctuations in the locomotor 
activity of animals. Therefore, the experiments were always performed in 
randomized order, that is, wild-type mice were always used in parallel with 
genetically modified animals.  
Sensitization of animals to amphetamine was also measured using the same 
motility boxes with similar environmental conditions. For this, the animals were 
habituated for two days and on the third day the experiment started. Animals 
were injected with 2.5 mg/kg amphetamine, and placed into the motility boxes 
for 30 min once a day for 6 consecutive days. 
 
3.1.2. Locomotor activity of drug-naive mice  
in the motility boxes (II) 
In paper II, one group of animals were taken for decapitation straight from their 
home cages and the other, also a drug-naive group were taken after a loco-
motion measurement box challenge. (For further details see paragraph 4 of 
Materials and methods.) 
 
24 
3.1.3. Administration of ethanol (III) 
In paper III, the animals were placed singly into the same motility boxes as in 
papers I and II, for 30 min. The distance travelled (m), time in locomotion (s) 
and the number of rearings were registered. 
 
3.2. Behavioral despair tests (II) 
3.2.1 Tail suspension test (II) 
The TST has been extensively validated with a wide range of antidepressants 
(Porsolt et al 1987). Most of the antidepressants maximally reduce the duration 
of immobility in the TST with doses less than those required for the FST (Liu & 
Gershenfeld, 2001). This test has been used alongside FST because hyper-
activity may be a confounding issue in the FST. Mice were suspended from the 
edge of a shelf 58 cm above a tabletop by adhesive tape, placed approximately 
1 cm from the tip of the tail. Animals were allowed to hang for 6 min and the 
duration of immobility was scored during the last 4 min from videotapes by an 
observer blind to the treatment protocol. Mice were considered immobile only 
when they hung passively and completely motionless. 
 
3.2.2. Forced swim test (II) 
The FST was performed as described by (Porsolt et al., 1977). Briefly, a glass 
cylinder 12 cm in diameter was filled with 18 cm water at 25 °C. The animal 
was gently put in the water, and the behavior recorded during 6 min. 
Subsequently, the immobility time was counted for the last 4 min of the test by 
an observer blind to the treatment protocol. 
 
3.3. Elevated plus-maze (III) 
The plus-maze consisted of two opposite open (17.5 cm × 5 cm) arms without 
sidewalls and two enclosed arms of the same size with 14 cm high sidewalls 
and an end wall. The entire plus-maze apparatus was elevated to a height of 
30 cm and placed in a brightly lit room (illumination level: around 500 lx in the 
open arms). Standard 5 min test duration was employed (Lister, 1987) and the 
maze was cleaned thoroughly with 5% alcohol and dried between the subjects. 
The following parameters were observed: (1) percentage (%) of time spent in 
the open arms, (2) % of open arm entries (3) number of unprotected head 
dippings (4) number of closed arm entries. % of time spent in the open arms and 
% of open arm entries are spatiotemporal measures of anxiety whereas the 
number of unprotected head dippings is an ethological measure which can be 
considered “risk assessment” behavior (Rodgers and Johnson, 1995). 
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3.4. Motor coordination in the rotarod test (III) 
Rotarod is one of the standard tests to measure coordination, balance and motor 
skill learning. The learning effect appears as the elongated falling latency with 
the trial numbers (Shiotsuki et al., 2010). This test also enables to evaluate 
sedation (Soderpalm et al., 1989, Steiner et al., 2011). The equipment consisted 
of a motor-driven drum (3 cm in diameter) rotating at fixed speed (9 rpm). Five 
minutes before the first trial on the rotarod, mice were habituated to stay on the 
drum for one minute. In later trials, habituation was not used. The second and 
third trials were conducted after 2 h and 24 h, respectively. The effect of ethanol 
on motor coordination was measured on the fourth trial (after 48 h). The time of 
maximal performance for each trial was set at 120 s. The animal was placed on 
the rotating drum and the latency (s) to the first fall from the drum was 
registered manually. Immediately after the fall, the mouse was put back on 
drum and the total number of falls was counted. 
 
3.5. Loss of righting reflex test (III) 
The mice were given an intraperitoneal injection of 4 g/kg of ethanol (20%, 
v/v), pentobarbital (45 mg/kg) or ketamine (150 mg/kg), placed in supine 
position in a V-shaped cardboard trough and tested for the ability to right itself. 
It was considered that the animal had lost the righting reflex if it could not right 
itself on all four paws three times within 30 s and regained the righting reflex if 
it could fully right itself three times within 30 s. The onset of drug-induced 
sedation (the onset of LORR) and the duration of LORR [time (min) between 
the loss of righting reflex and the regain of righting reflex] were measured. 
 
 
4. Tissue monoamine content measurements  
by HPLC (I, II) 
In paper I, mice were randomly divided into groups that received an injection of 
only saline, amphetamine (5 mg/kg) or apomorphine (3 mg/kg). After adminis-
tration of saline or the DA agonists the animals were placed into the above 
described motility boxes (TSE, Germany) where their locomotor activity was 
assessed. This procedure lasted 30 min after which the mice were decapitated 
and their brains rapidly removed. There was also one group of mice taken 
directly from their home-cages in order to measure the effect of exposure of 
mice to the motility boxes. Two brain regions were dissected – the dorsal 
(encompassing the CPu) and ventral striatum (encompassing the nucleus 
accumbens and olfactory tubercle) – and frozen in liquid nitrogen. The 
dissection was performed according to the coordinates presented in the mouse 
brain atlas by Franklin and Paxinos (Franklin & Paxinos, 1997). DA and its 
metabolites were assayed by high performance liquid chromatography (HPLC) 
with electrochemical detection. We measured the tissue levels of DA (DA) and 
7
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its metabolites – 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) in pmol/mg of tissue weight. Finally, 
DA turnover was calculated as the ratio between the tissue levels of DA end-
metabolite HVA and DA itself (HVA/DA). 
In paper II, 5-HT and NA were measured in two groups: mice exposed for 
30 min to the brightly lit motility boxes (exposure group) and mice taken directly 
from their home-cages (naïve group). The animals were immediately decapitated 
after completing the experiment in the motility boxes or after taking them out 
from their home-cage. Again, the animals were transported to a separate room for 
the decapitation. The dorsal (encompassing the nucleus caudatus and putamen) 
striatum and the ventral (encompassing the nucleus accumbens and tuberculum 
olfactorium) striatum were dissected according to coordinates by Franklin and 
Paxinos (1997). The dissected tissues were promptly frozen in liquid nitrogen. 
Tissue levels of 5-HT and NA (in pmol/mg) were determined using HPLC with 
electrochemical detection. Additionally, their respective metabolites 5-hydroxyin-
doleacetic acid (5-HIAA) and normetanephrine (NMN) were assayed. 
The following homogenization and HPLC protocol was used in papers I and 
II. The tissue samples were homogenized with Bandelin Sonopuls ultrasonic 
homogenizer (Bandelin Electronic, Berlin, Germany) in ice-cold solution of 
0.1 M perchloric acid (10–30 μl/mg) containing 5 mM sodium bisulphite and 
0.4 mM EDTA to avoid oxidation. The homogenate was then centrifuged at 
17,000 × g for 10 min at 4 °C. Aliquots (10 μl) of the obtained supernatant were 
chromatographed on a Lichrospher 60 RP Select B column (250 × 3 mm; 5 μm). 
The separation was done in isocratic elution mode at column temperature of 
30 °C using the mobile phase containing 0.05 M sodium citrate buffer at pH 3.7; 
0.02 mM EDTA; 1 mM KCl; 1 mM sodium octylsulphonate and 5.6% aceto-
nitrile. The chromatography system consisted of a Hewlett Packard HP 1100 
Series isocratic pump, a thermostated autosampler, a thermostated column 
compartment and an HP 1049 electrochemical detector (Agilent, Waldbronn, 
Germany) with glassy carbon electrode. The measurements were done at an 
electrode potential of + 0.7 V versus the Ag/AgCl reference electrode.  
 
 
5. Gene expression analysis by qRT-PCR (I, II, III) 
5.1. RNA isolation and cDNA synthesis 
These studies – with the exception of paper III, details given below – were done 
on drug-naive groups of animals taken directly from their home-cages. Mice were 
decapitated immediately after taking them out from their home-cage and bringing 
them into the room where the decapitations took place. The gene expression 
studies in wild-type, heterozygous and homozygous animals were conducted in 
parallel. Total RNA was extracted individually from each brain structure of each 
mouse using Trizol® Reagent (Invitrogen, USA) according to the manufacturer’s 
protocol. First strand cDNA was synthesized by using poly (T)18 oligo-
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nucleotides and SuperScript™ III Reverse Transcriptase (Invitrogen, USA). In 
paper I the measurements were performed on the midbrain (DAT) and the dorsal 
and ventral striatum (Drd2) of the respective mice. In paper II the midbrain 
(SERT) and pons (SERT and NAT) were dissected and frozen in liquid nitrogen. 
In paper III, the acute effect of ethanol (2 g/kg) was investigated on Gabra1, 
Gabra2 and Gabra3 mRNA in wild-type and homozygous Wfs1-deficient mice. 
The animals were decapitated in a separate room 30 and 60 min after ethanol or 
30 min after vehicle injection (ethanol 30, ethanol 60 and vehicle group, 
respectively). The frontal cortex (including the prefrontal cortex) and temporal 
lobe were dissected according to the coordinates provided in the mouse brain 
atlas (Franklin & Paxinos, 1997). For dissection of the temporal lobe, the 
anterior coronal cut was performed on the level of anterior border of hypo-
thalamus and the second cut was done 2.5 mm behind that line. The temporal 
lobe was bilaterally dissected from the lower lateral corner of this slice, 
containing the piriform cortex and, basolateral, central and medial nuclei of 
amygdala. The dissected brain structures were quickly frozen in liquid nitrogen. 
 
5.2. qRT-PCR 
For qRT-PCR analysis, the ABI PRISM 7900HT Fast Real-Time PCR System 
equipment (PE Applied Biosystems, USA) and the ABI PRISM 7900 SDS 2.2.2 
Software were used. Every reaction was made in four parallel samples to 
minimize possible errors. All reactions were performed in a final volume of 
10 μl, using 50–100 ng of cDNA. Taqman assays (PE Applied Biosystems) for 
genes measured in papers I–III, see Table 1. 
 
Table 1. The Taqman assays and probes used in each paper 
Gene symbol Paper Assay ID or sequence Gene ID 
Slc6a3 (DAT)  I Mm00438396_m1 NM_010020  
Drd2 (D2) I Mm00438545_m1 NM_010077.2 
Slc6a2 (NAT) II Mm00436661_m1 NM_009209.3 
Slc6a4 (SERT) II Mm00439391_m1 NM_010484.2 
Gabra1 III Mm00439046_m NM_010250 
Gabra2 III Mm00433435_m1 NM_008066 
Gabra3 III Mm01294271_m1 NM_008067 
Hprt1 for I, II, III 5’-GCAGTACAGCCCCAAAATGG-3’  
Hprt1 rev I, II, III 5’- AACAAAGTCTGGCCTGTATCCAA-3’ NM_013556 
Hprt1 probe 
(VIC_TAMRA) 
I, II, 
III 
5’-VIC-AAGCTTGCTGGTGAAAAGG-
ACCTCTCG TAMRA-3’ 
 
DAT – DA transporter gene; Slc6a3 – solute carrier family 6 (neurotransmitter transporter, DA), 
member 3; Drd2 – DA D2 receptor gene; Slc6a2 – solute carrier family 6 (neurotransmitter 
transporter, NA), member 2; Slc6a4 – solute carrier family 6 (neurotransmitter transporter, 5-HT), 
member 4; Hprt1 – hypoxanthine phosphoribosyltransferase 1 gene. 
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6. Western blotting (I) 
The protein measurements were performed on separate groups of animals taken 
directly from their home-cages. Brains were removed and the dorsal striatum 
dissected. Protein extraction was performed using the PARIS kit (Life Techno-
logies) supplemented with Protease inhibitor cocktail (Thermo Scientific) as 
described by Raida et al (2012). The tissues were sonicated and centrifuged for 
10 min 12,000g at 4 °C. The supernatants were kept on –80 °C and the protein 
concentrations were measured by BCA method. Reagents and equipment for 
electrophoreses and protein transfer was used according to manufacture’s 
guidelines regarding the NuPAGE system (Life Technologies) and described 
previously (Raida et al., 2012). 
For western blotting, membranes were blocked for one hour in 3% BSA in 
PBS. Following blocking the membranes were incubated with a primary 
antibody (Table 2). After primary antibody incubation the membranes were 
washed 6 times in Milli-Q water and incubated with the respective secondary 
antibodies (Table 3) for one hour at RT. After secondary antibody incubations 
the membranes were washed 6 times in Milli-Q water followed by a 20 min 
wash step in PBS–0,1% Tween-20. Prior to signal detection the membranes 
were washed 6 times in Milli-Q water. Antibody detection was performed using 
the Li-Cor Odyssey CLx system (Li-Cor biotechnologies). Images were 
converted to grayscale and quantification was performed using the Gel-analyzer 
plugin in ImageJ following NIH guidelines. 
 
Table 2. The primary antibodies 
Protein Paper Species Company Cat # Dilution 
DAT I Rat Santa Cruz Biot. sc-32258 1:1K 
ß-actin I, III Rabbit Cell Signaling 4970 1:10K 
DAT – DA transporter. 
 
Table 3. The secondary antibodies 
Species Anti Company Dilution Conjugant Cat # 
Donkey Rabbit Jackson ImmunoResearch 1:40K Alexa-790 711-655-152 
Donkey Rat Jackson ImmunoResearch 1:40K Alexa-680 712-625-150 
 
7. Statistical analyses (I, II, III) 
Mean values and S.E.M. are presented in all the figures and tables. All data 
were analyzed using Statistica version 8.0 (StatSoft, Inc., USA). Results were 
considered statistically significant when p<0.05. 
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In paper I, one-way analysis of variance (ANOVA) was applied in the gene 
expression experiments and Mann-Whitney U test was used for the protein 
expression studies. Two-way ANOVA (genotype and treatment as independent 
measures) was performed in the experiments measuring the locomotor activity 
and brain DA levels. A three-way repeated measures ANOVA (genotype × 
treatment × day) was used in the experiment measuring sensitization to 
amphetamine. Tukey HSD post-hoc analysis was used when applicable after 
significant ANOVA. 
In paper II, the results of the behavioral and gene expression studies are 
expressed as mean values ± SEM. Since there were no significant sex 
differences in the results of any of the performed experiments, and to raise the 
statistical power of the study, data from male and female animals were pooled. 
The results of the TST and FST were analysed using two-way ANOVA 
(genotype × treatment). One-way ANOVA was applied for the statistical 
analysis of gene expression data. The results of monoamine and their metabolite 
assays were analysed using two-way ANOVA (genotype × exposure). Post-hoc 
comparisons were performed using Scheffe or Tukey HSD tests. 
In paper III, the results are expressed as mean values ± S.E.M. The results of 
the elevated plus-maze and locomotor activity tests were analyzed using two-
way independent groups ANOVA (genotype × ethanol treatment). Data from 
the rotarod measurements were analyzed using repeated measures ANOVA 
with 1 within-subjects variable (trial) and two-way ANOVA (genotype × 
ethanol treatment). The results of the LORR test were analyzed with one-way 
ANOVA. Two-way ANOVA was applied to analyze gene expression studies 
(genotype × ethanol treatment). Post-hoc comparisons were performed by 
means of Newman-Keuls test. 
 
 
8. Ethics permit (I, II, III) 
The permission for the studies was given by the Estonian National Board of 
Animal Experiments (No. 13 from 16.09.2009) in accordance with the 
European Communities Directive of November 1986 (86/609/EEC) 
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RESULTS  
1. Paper I 
1.1. DA measurement in the dorsal and ventral striatum 
1.1.1. Effect of exposure of mice to the motility boxes 
The levels of DA and its major metabolites were compared in mice exposed to 
the motility boxes for 30 min and in animals taken directly from their home-
cages. Both female and male mice were used for this study. However, the 
statistical analysis did not reveal any sex-dependent differences and, therefore, 
the data obtained from the female and male mice were pooled.  
As in the previous study (Luuk et al 2009), the locomotor activity of 
homozygous mice tended to be lower compared to the other genotypes. 
However, the application of one-way ANOVA did not reveal any statistically 
significant differences in motor activity between the genotypes (data not 
shown).  
Exposure of mice to the motility boxes caused a statistically significant 
change in the metabolism of DA in the dorsal and ventral striatum (Table 4, A 
and B). A genotype as well as exposure effect was established for homovanillic 
acid (HVA), a major metabolite of DA, in the dorsal striatum (genotype effect: 
F2,51=3.53, p<0.036; exposure effect: F1,51=34.9, p<0.001, genotype × 
exposure effect: F2,51=0,87, p=0.42 Table 4A). Exposure to the motility boxes 
also changed the ratio between HVA and DA (DA turnover) (F1,51=57.0, 
p<0.001) in the dorsal striatum (Figure 1). Post-hoc analysis (Tukey HSD test) 
established that exposure to the motility boxes induced a significant increase in 
the levels of HVA in wild-type and heterozygous mice, but not in homozygous 
animals. By contrast, the increase in DA turnover was significantly elevated in 
all genotypes (Figure 1). In the ventral striatum, an exposure effect was 
established for HVA (F1,46=31.3, p<0.001)(Table 4B). The exposure effect 
was also significant (F1,46=11.1, p<0.01) for DA turnover in the ventral 
striatum (Figure 1), but post-hoc analysis did not establish any significant 
changes between the groups. 
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Table 4. Effect of exposure of Wfs1-deficient mice to the motility boxes compared to 
mice taken from the home cage on the metabolism of DA in the dorsal and ventral 
striatum. 
  Wild-
type 
Wild-
type+ 
exposure 
Hetero-
zygous 
Hetero-
zygous+ 
exposure 
Homo-
zygous 
Homo-
zygous+ 
exposure 
(A) 
Dorsal 
striatum 
DA 46.1±3.2 46.6±3.4* 52.2±4.8 49.1±2.6* 50.5±3.4 46.0±2.8 
DOPAC 6.5±1.0 7.9±0.7* 7.6±1.0 9.1±0.8* 7.4±0.8 6.8±1.2 
HVA 3.9±0.3 6.3±0.5* 4.9±0.5 7.4±0.5* 4.4±0.3 5.9±0.5 
3-MT 2.6±0.2 3.5±0.4* 3.2±0.4 3.3±0.2* 3.3±0.3 2.8±0.3 
(B) 
Ventral 
striatum 
DA 26.5±3.0 30.5±4.5* 33.7±3.9 35.0±4.0* 25.8±2.3 29.6±2.7 
DOPAC 5.7±0.9 5.8±0.7* 4.9±0.4 7.4±1.1* 5.1±0.6 3.9±0.6 
HVA 3.7±0.4 5.8±0.5* 4.1±0.2 6.5±0.7* 3.6±0.2 5.0±0.3 
3-MT 3.6±0.2 3.8±0.2* 3.2±0.3 3.9±0.5* 2.9±0.2 2.5±0.2 
Mean values ± SEM are presented in the table. Data are expressed as pmol/mg of tissue weight.  
* – p<0.05 compared to the respective group of naive mice (Tukey HSD test after significant two-
way ANOVA). DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – Homovanillic acid; 3-MT – 
3-Methoxytyramine. There were 5 male and 5 female mice in each group. 
 
 
 
Figure 1. Effect of exposure to the motility boxes on DA turnover in the dorsal and 
ventral striatum. * – p<0.05 compared to respective group of mice not exposed to the 
motility boxes (Tukey HSD test after significant two-way ANOVA). Data are expressed 
as ratio between the levels of HVA (pmol/mg) and DA (pmol/mg) in the respective 
brain structures. There were 5 male and 5 female mice in each group. 
 
1.1.2. Effect of amphetamine on locomotor activity and  
DA metabolism 
30 minutes after treatment with amphetamine (5 mg/kg), animals were placed 
into the motility boxes and their locomotor activity was measured. As a result, a 
gene-dose effect on amphetamine-induced hyperlocomotion was established 
(Figure 2). Altogether, similarly to our previous study (Luuk et al., 2009), 
amphetamine-induced locomotor stimulation was clearly stronger in wild-type 
32 
mice compared to their heterozygous and homozygous littermates. Two-way 
ANOVA revealed significant effects of genotype and treatment on all measures 
of motor activity (genotype effects: time in locomotion F2,53=9.78, p<0.001, 
distance travelled F2,53=8.82, p<0.001, number of corner entries F2,53=5.57, 
p<0.01; treatment effects: time in locomotion F1,53=54.0, p<0.001, distance 
travelled F1,53=55.7, p<0.001; number of corner entries F1,53=43.4, p<0.001; 
genotype and treatment interactions: time in locomotion F2,53=3.62, p<0.05, 
distance travelled F2,53=5.94, p<0.01, number of corner entries F2,53=4.83, 
p<0.05). According to post-hoc analysis, the elevation of all measures of loco-
motor activity of amphetamine-treated wild-type and heterozygous mice was 
statistically significant compared to the respective saline-treated groups 
(p<0.05, Tukey HSD) (Figure 2). There was a significant difference between 
amphetamine-treated wild-type and homozygous mice for all measures of 
locomotor activity (p<0.05, Tukey HSD). The difference in distance travelled 
after treatment with amphetamine was also significant when wild-type and 
heterozygous mice were compared. 
 
Figure 2. Effect of amphetamine (5 mg/kg) on the locomotor activity. * – p<0.05 
compared to the respective group of saline treated mice (Tukey HSD test after 
significant two-way ANOVA); + – p<0.05 (compared to amphetamine-treated wild-type 
mice). There were 5 male and 5 female mice in each group. 
 
 
In the biochemical studies, treatment with amphetamine caused significant 
changes in DA metabolism in the dorsal and ventral striatum. In the dorsal 
striatum, genotype effect was significant for DA (F2,53=3.50, p<0.05) and for 
its metabolite 3-MT (F2,53=5.99, p<0.01) (Table 5A). Treatment effect was 
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significant for DA (F1,53=19.2, p<0.001), DOPAC (F1,53=44.7, p<0.001), 
HVA (F1,53=24.0, p<0.001), 3-MT (F1,53=11.5, p<0.01) (Table 5A) and DA 
turnover (F1,53=68.3, p<0.001) (Figure 3). Genotype and treatment interaction 
was established for DA (F2,53=3.19, p<0.05) and for DA turnover it was close 
to being significant (F2,53=2.74, p=0.07). Amphetamine was found to increase 
the levels of DA and lower DOPAC and DA turnover in the dorsal striatum of 
wild-type mice when compared to saline-treated wild-type mice (p<0.05, Tukey 
HSD test) (Table 5A, Figure 3). In heterozygous mice, amphetamine caused a 
significant reduction DOPAC and HVA levels, but also increased the level of  
3-MT. Moreover, DA turnover was also reduced in these mice. We found a 
reduction of DOPAC in response to amphetamine in homozygous mice. Besides 
that, homozygous mice displayed significantly lower levels of DA and 3-MT in 
the dorsal striatum in response to amphetamine compared to their wild-type 
littermates. 
In the ventral striatum, a genotype effect was established for DOPAC 
(F2,49=8.92, p<0.001) and 3-MT (F2,49=12.5, p<0.001) (Table 5B). Treatment 
effect was significant for DA (F1,49=4.68, p<0.05), DOPAC (F1,49=9.16, 
p<0.01), HVA (F1,49=8.99, p<0.01), 3-MT (F1,49=9.41, p<0.01) and DA 
turnover (F1,49=24.7, p<0.001). The interaction of genotype with treatment was 
close to statistical significance in the case of DA turnover (F2,49=2.80, p=0.07). 
In wild-type mice, amphetamine induced a significant increase in the level of 
DA and reduced DA turnover (Table 5B, Figure 3). In heterozygous mice, an 
increase in the level of 3-MT was evident. Also, the levels of DOPAC, HVA and 
the turnover of DA were reduced in heterozygous mice. The level of 3-MT in 
homozygous mice, after treatment with amphetamine, was significantly lower 
compared to heterozygous and wild-type animals. Amphetamine did not induce a 
significant reduction of DA turnover in the ventral striatum of homozygous mice. 
Altogether, the strongest differences between the genotypes were established for 
the elevation of DA levels under the influence of amphetamine in the dorsal and 
ventral striatum. There was a clear gene-dose effect similar to that established 
for amphetamine-induced hyperlocomotion (Figure 2 and Table 5A and 5B). 
Moreover, amphetamine was not able to induce a statistically significant sup-
pression of DA turnover in the dorsal and ventral striatum of homozygous mice. 
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Table 5. Effect of amphetamine (5 mg/kg) on the metabolism of DA in the dorsal and 
ventral striatum of Wfs1-deficient mice. 
  Wild-
type+ 
saline 
Wild-
type+ 
amphet-
amine 
Hetero-
zygous+ 
saline 
Hetero-
zygous+ 
amphet-
amine 
Homo-
zygous+ 
saline 
Homo-
zygous+ 
amphet-
amine 
 
(A) 
Dorsal 
striatum 
DA 46.6±3.4 69.3±6.1*+ 49.1±2.6 63.6±2.9+* 46.0±2.8 50.7±4.2+ 
DOPAC 7.9±0.7 4.5±0.5*+ 9.1±0.8 3.7±0.6*+ 6.8±1.2 3.0±0.6* 
HVA 6.3±0.5 4.7±0.4+* 7.4±0.5 4.5±0.7*+ 5.9±0.5 4.3±0.4+ 
3-MT 3.5±0.4 4.4±0.5+* 3.3±0.2 5.3±0.6*+ 2.8±0.3 3.2±0.2+ 
 
(B) 
Ventral 
striatum 
DA 30.5±4.5 46.0±5.0*+ 35.0±4.0 42.3±4.0*+ 29.6±2.7 31.7±3.3+ 
DOPAC 5.8±0.7 4.5±0.8+* 7.4±1.1 4.9±0.9*+ 3.9±0.6 2.1±0.4+ 
HVA 5.8±0.5 4.1±0.6+* 6.5±0.7 4.4±0.4*+ 5.0±0.3 4.9±0.7+ 
3-MT 3.8±0.2 4.8±0.7+* 3.9±0.5 5.5±0.5*+ 2.5±0.2 3.0±0.3+ 
Mean values ± SEM are presented in the table. Data are expressed as pmol/mg of tissue weight.   
* – p<0.05 compared to the respective group of saline treated mice (Tukey HSD test after 
significant two-way ANOVA); + – p<0.05 compared to homozygous mice treated with 
amphetamine. DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – Homovanillic acid; 3-MT – 3-
Methoxytyramine. There were 5 male and 5 female mice in each group. 
 
 
Figure 3. Effect of amphetamine (5 mg/kg) on the turnover of DA in the dorsal and 
ventral striatum. * – p<0.05 compared to respective group of saline treated mice 
(Tukey HSD test after significant two-way ANOVA). Data are expressed as ratio 
between the levels of HVA (pmol/mg) and DA (pmol/mg) in the respective brain 
structures. There were 5 male and 5 female mice in each group. 
 
1.1.3. Effect of apomorphine on locomotor activity and  
DA metabolism 
In the case of treatment with apomorphine, a two-way ANOVA established that 
only treatment effect was significant for all measures of locomotor activity 
(time spent in locomotion F1,54=15.3, p<0.001, distance travelled F1,54=11.3, 
p<0.01 and the number of corner entries F1,54=16.7, p<0.001). Administration 
of apomorphine (3 mg/kg) tended to increase the locomotor activity in wild-
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type mice, but this effect was not statistically significant (Figure 4). 
Apomorphine-treated heterozygous mice displayed significantly longer distance 
travelled and a greater number of corner entries compared to saline-treated 
heterozygous mice. Homozygous Wfs1-deficient mice had a significant increase 
in time spent in locomotion compared to the respective saline-treated group 
(p<0.05, Tukey HSD). 
 
Figure 4. Apomorphine (3 mg/kg) induced changes in locomotor activity of Wfs1-
deficient mice. * – p<0.05 compared to the respective group of saline treated mice 
(Tukey HSD test after significant two-way ANOVA). There were 5 male and 5 female 
mice in each group. 
 
 
In the dorsal striatum, treatment effect of apomorphine was significant for 
DOPAC (F1,52=43.8, p<0.001), HVA (F1,52=117.2, p<0.001) (Table 6A) and 
DA turnover (F1,52=95.1, p<0.001) (Figure 5). Genotype and treatment inter-
action was significant for HVA (F2,52=3.26, p<0.05). Apomorphine signi-
ficantly reduced the levels of HVA, DOPAC, and DA turnover in the dorsal 
striatum of all genotypes. 
In the ventral striatum, treatment effect of apomorphine was significant for 
DOPAC (F1,50=8.97, p<0.01), HVA (F1,50=57.9, p<0.001), 3-MT (F1,50=5.38, 
p<0.05) (Table 6B), and DA turnover (F1,50=58.1, p<0.001) (Figure 5). Apo-
morphine caused a significant reduction of HVA and DA turnover in the ventral 
striatum of all genotypes. In heterozygous mice, the level of DOPAC was also 
reduced in the ventral striatum in response to apomorphine. 
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Table 6. Effect of exposure to apomorphine (3 mg/kg) on the metabolism of DA in the 
dorsal and ventral striatum in Wfs1-deficient mice 
  Wild-
type+ 
saline 
Wild-
type+ apo-
morphine 
Hetero-
zygous+ 
saline 
Hetero-
zygous+ 
apo-
morphine 
Homo-
zygous+ 
saline 
Homo-
zygous+ 
apo-
morphine 
 
(A) 
Dorsal 
striatum 
DA 46.6±3.4 49.9±3.3* 49.1±2.6 43.3±3.1* 46.0±2.8 52.7±3.4* 
DOPAC 7.9±0.7 4.3±0.5* 9.1±0.8 3.3±0.8* 6.8±1.2 3.4±0.4* 
HVA 6.3±0.5 3.3±0.5* 7.4±0.5 2.4±0.3* 5.9±0.5 2.5±0.2* 
3-MT 3.5±0.4 2.7±0.2* 3.3±0.2 2.4±0.3* 2.8±0.3 2.1±0.2* 
 
(B) 
Ventral 
striatum 
DA 30.5±4.5 28.0±5.3* 35.0±4.0 35.1±3.8* 29.6±2.7 39.3±6.5* 
DOPAC 5.8±0.7 4.8±1.0* 7.4±1.1 3.9±0.4* 3.9±0.6 3.1±0.4* 
HVA 5.8±0.5 2.9±0.5* 6.5±0.7 3.1±0.4* 5.0±0.3 2.8±0.4* 
3-MT 3.8±0.2 3.0±0.5* 3.9±0.5 3.1±0.5* 2.5±0.2 1.9±0.2* 
Mean values ± SEM are presented in the table. Data are expressed as pmol/mg of tissue 
weight. * – p<0.05 compared to the respective group of saline treated mice (Tukey HSD 
test after significant two-way ANOVA). DOPAC – 3,4-Dihydroxyphenylacetic acid; 
HVA – Homovanillic acid; 3-MT – 3-Methoxytyramine. There were 5 male and 5 female 
mice in each group. 
 
 
Figure 5. Effect of apomorphine (3 mg/kg) on the turnover of DA in the dorsal and 
ventral striatum. * – p<0.05 compared to the respective group of saline treated mice 
(Tukey HSD test after significant two-way ANOVA). Data are expressed as ratio 
between the levels of HVA (pmol/mg) and DA (pmol/mg) in the respective brain 
structures. There were 5 male and 5 female mice in each group. 
 
1.2. Amphetamine-induced motor sensitization 
During the course of repeated treatments with amphetamine (2.5 mg/kg) its 
motor stimulating effect became steadily stronger in male wild-type animals. 
Repeated measures three-way ANOVA established the following main and 
interaction effects: time in locomotion [F2,76=10.2, p<0.001 (genotype); 
F5,76=4.1, p<0.01 (day); F5,76=13.9, p<0.001 (day × treatment)], distance 
37 
travelled [F2,76=6.33, p<0.01 (genotype); F1,76=6.92, p<0.05, (treatment); 
F5,76=9.74, p=0.09 (day × treatment)] and number of corner entries [F2,76=3.29, 
p<0.05 (genotype); F1,76=7.2, p<0.01 (treatment), F5,76=5.28, p<0.01 (day × 
treatment)]. 
Post-hoc analysis (Tukey HSD test) revealed that in wild-type mice the 
effect of amphetamine on the 6th day was significantly increased compared to the 
administration of saline on the 6th day and to the treatment with amphetamine 
on the 1st day (Figure 6). In heterozygous mice, there was some increase in the 
action of amphetamine, but this change was not statistically significant. 
Repeated treatments with amphetamine tended to reduce the locomotor activity 
in homozygous mice (Figure 6). Therefore, in the amphetamine sensitization 
study, a gene-dose effect was established in Wfs1-deficient mice as in the case 
of acute treatment with the higher dose of amphetamine (5 mg/kg). 
 
 
Figure 6. Sensitization of Wfs1-deficient mice to amphetamine-induced motor 
stimulation. * – p<0.05 compared to amphetamine-treated wild-type mice on the first 
day; ¤ – p<0.05 compared to saline-treated wild-type mice on the sixth day; # – p<0.05 
compared to amphetamine-treated homozygous mice on the 6th day. (Tukey HSD after 
significant three-way repeated measures ANOVA.) The number of animals in each 
group was 13–14. 
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1.3. Expression of DAT (midbrain) and Drd2 (striatum) mRNA 
The expression level of DAT mRNA in the midbrain was significantly affected 
in male and female mice (F2,20=3.95, p<0.05 and F2,47=4.82, p<0.05, 
respectively). Post-hoc analysis established a significantly lower level of DAT 
expression in homozygous animals of both sexes (Figures 7A and 7B). 
The expression level of Drd2 gene in the ventral striatum of both male and 
female mice was not affected by the disruption of the Wfs1 gene (Figures 8B 
and 8D). However, we found a significantly reduced Drd2 receptor level in the 
dorsal striatum of male homozygous mice compared to wild-type animals 
(F2,15=6.32, p<0.05) (Figure 8A), while in the female mice it was unaffected 
(Figure 8C).  
 
Figure 7. Expression of DAT gene in the midbrain. A. DAT mRNA in the midbrain 
of female mice; B. DAT mRNA in the midbrain of male mice. * – p<0.05 compared to 
wild-type animals (Tukey HSD after significant one-way ANOVA). The number of 
animals in each group was 16–17 in case of females and 7–8 in case of males. 
 
Figure 8. Expression of Drd2 gene in the dorsal and ventral striatum. Relative 
Drd2 mRNA levels in the dorsal (A) and ventral striatum (B) of male mice and relative 
Drd2 levels in the dorsal (C) and ventral striatum (D) in female mice. * – p<0.05 com-
pared to wild-type animals (Tukey HSD after significant one-way ANOVA). The number 
of animals in each group was 16–17 in case of females and 7–8 in case of males. 
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1.4. Expression of DAT protein in the dorsal and  
ventral striatum 
There was no significant effect of genotype on DAT protein expression in either 
male or female mice, in the dorsal and ventral striatum (Mann-Whitney U-test, 
p>0.05).  
 
 
2. Paper II 
2.1. Tail suspension test (imipramine and paroxetine) 
There was no difference in the basal immobility levels between genotypes. It 
was found that in homozygous Wfs1-deficient mice, imipramine induced a 
significant decrease in immobility time at doses of 10 mg/kg and 20 mg/kg as 
compared to vehicle treated homozygous mice (Figure 9). In both heterozygous 
and wild-type animals, only 20 mg/kg of imipramine was effective at signi-
ficantly lowering immobility time compared to the respective vehicle-treated 
group of the same genotype. 
 
 
Figure 9. Effect of imipramine on the immobility time of Wfs1-deficient mice in the 
TST. * – p<0.01 compared to vehicle-treated mice of the same genotype (Scheffe post-
hoc test after significant two-way ANOVA). Altogether, 70 wild-type, 67 heterozygous 
and 71 homozygous mice were used. Mice were randomly divided between respective 
study groups. Genotype (F2,199=4.2, p<0.05); treatment (F2,199=84.1, p<0.01); 
genotype × treatment (F4,199=3.5, p<0.01). 
 
 
In the study where the effect of paroxetine was investigated, the basal 
immobility levels of all genotypes showed no statistically significant difference. 
In homozygous Wfs1-deficient mice, paroxetine induced a significant decrease 
in immobility time already at a dose of 5 mg/kg compared to vehicle group 
from the same genotype (Figure 10). For heterozygous animals, a significant 
difference in immobility time between vehicle-treated and drug-treated mice 
was established at doses of 20 and 30 mg/kg of paroxetine. In wild-type mice, 
only the highest dose (30 mg/kg) led to a significant reduction in immobility 
time compared to vehicle group from the same genotype (Figure 11). 
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Figure 10. Effect of paroxetine on the immobility time of Wfs1-deficient mice in 
the TST. * – p<0.01 compared to vehicle-treated mice of the same genotype (Scheffe 
post-hoc test after significant two-way ANOVA). Altogether, 93 wild-type, 95 
heterozygous and 91 homozygous mice were used. Mice were randomly divided 
between respective study groups. Genotype (F2,264=7.1, p<0.01); treatment 
(F4,264=41.4, p<0.01); genotype × treatment (F8,264=1.02, p=0.42). 
  
2.2. Forced swimming test (imipramine) 
In contrast to the TST, effective doses of imipramine were somewhat higher in 
this test. These results are in accordance with previous findings (Liu and 
Gershenfeld, 2001). As in the TST, basal immobility levels were similar across 
genotypes. For homozygous mice, a remarkable reduction in immobility behavior 
was observed at 20 and 30 mg/kg doses compared to vehicle-treated mice from 
the same genotype (Figure 11). Compared to vehicle received heterozygous mice, 
heterozygous animals treated with 20 mg/kg of imipramine exhibited significant 
decrease in immobility time whereas the highest dose (30 mg/kg) had no 
statistical effect. Finally, wild-type animals were sensitive only to the highest 
dose of imipramine as compared to drug-naïve wild-type mice (Figure 11). 
 
Figure 11. Effect of imipramine on the immobility time of Wfs1-deficient mice in 
the FST. * – p <0.05, ** – p<0.01 compared to vehicle-treated mice of the same 
genotype (Scheffe post-hoc test after significant two-way ANOVA). Altogether, 77 
wild-type, 80 heterozygous and 79 homozygous mice were used. Mice were randomly 
divided between respective study groups. Genotype (F2,224=5.9, p<0.01); treatment 
(F3,212=37.1, p<0.01); genotype × treatment (F6,224=1.7, p=0.13). 
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2.3. Gene expression studies 
In the pons, the expression of SERT was significantly lower in homozygous 
mice compared to their wild-type littermates (Figure 12A). The level of SERT 
mRNA in the midbrain was not changed in Wfs1-deficient mice (Figure 12C). 
The expression of NAT was lower in Wfs1-deficient mice in the pons compared 
to wild-type mice, but this difference did not reach statistical significance 
(Figure 12B). Furthermore, the levels of NAT mRNA in the midbrain were 
below detection limit and, consequently, these data are not presented. 
 
 
Figure 12. Effect of Wfs1 gene invalidation on the expression of monoamine 
transporter genes in the pons (A and B) and midbrain (C). * – p<0.01 compared to 
wild-type mice (Tukey HSD test after significant one-way ANOVA). The number of mice 
in each group was 12–16. SERT (pons): genotype (F2,41=6.49, p<0.01); NAT (pons): 
genotype (F2,40=2.57, p=0.09). SERT (midbrain); genotype (F2,39=1.76, p=0.19).  
 
2.4. 5-HT and NA measurements 
There was no statistically significant difference in the locomotor activity of the 
three genotypes (data not shown). However, comparison between mice exposed 
to the motility boxes and experimentally naïve mice showed that exposure to 
the brightly lit motility boxes caused activation of the 5-HT-ergic, but not the 
NA-ergic, system in the dorsal and ventral striatum (Table 7). In the ventral 
striatum 5-HT and 5-HIAA levels were significantly increased in wild-type mice 
exposed to the motility boxes as compared to naïve wild-type littermates. The 
behavioral challenge failed to alter the levels of 5-HT and 5-HIAA in Wfs1-
deficient homozygous mice, compared to naïve Wfs1-deficient homozygous 
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mice (Table 7A). In heterozygous mice, this stressful challenge caused a rise in 
the levels of NA and 5-HIAA as compared to naïve heterozygous animals. 
In the dorsal striatum, 5-HIAA levels were significantly increased in wild-
type and heterozygous mice exposed to the motility boxes as compared to their 
respective naïve littermates. For homozygous animals, no difference was 
established in the level of 5-HIAA between the experimental and control groups 
(Table 7B). In wild-type mice, the level of 5-HT was not significantly increased 
(p=0.09), whereas in homozygous mice, the concentration of 5-HT was 
reduced. Consequently, a simultaneous rise in wild-type mice and a decline in 
homozygous animals was the reason for a significant genotype × exposure 
interaction in two-way ANOVA analysis of 5-HT levels. 
 
Table 7. Effect of exposure of Wfs1-deficient mice to the motility boxes on the 
levels of monoamines and their metabolism in the ventral and dorsal striatum. 
  Wild-
type 
Wild-
type+ 
exposure
Heterozy
gous 
Heterozygo
us + 
exposure 
Homo-
zygous 
Homo-
zygous+ 
exposure 
Ventral 
striatum 
(A) 
 
NA 1.9±0.3 2.4±0.4* 1.7±0.2 3.7±0.8** 2.7±0.4 1.8±0.3 
NMN 1.0±0.1 0.8±0.1* 0.8±0.1 1.0±0.1** 0.8±0.1 0.8±0.1 
5-HT 2.8±0.2 3.9±0.4* 3.2±0.1 3.3±0.2** 3.2±0.1 3.4±0.2 
5-HIAA 2.6±0.2 3.9±0.2* 2.7±0.2 3.7±0.2** 2.7±0.1 3.3±0.2 
Dorsal 
striatum 
(B) 
 
NA 2.4±0.3 2.8±0.6* 2.2±0.2 2.3±0.2** 3.1±0.7 2.7±0.2 
NMN 0.7±0.1 0.8±0.1* 0.8±0.1 0.9±0.1** 0.8±0.1 0.7±0.1 
5-HT 4.9±0.1 6.1±0.4* 5.2±0.1 5.8±0.3** 6.0±0.4 5.3±0.2 
5-HIAA 1.8±0.1 2.8±0.2* 2.0±0.2 3.3±0.2** 2.1±0.2 2.8±0.2 
p<0.05, **– p<0.01 compared to naïve mice from the same genotype (Tukey HSD test 
after significant two-way ANOVA). There were 8–10 mice in each group. 5-HT 
(ventral striatum): exposure effect (F1,46=5.62, p<0.05), 5-HIAA (ventral striatum): 
exposure effect (F1,46=34.4, p<0.01); NA (ventral striatum): genotype × exposure 
(F2,46=4.98, p<0.01); 5-HIAA (dorsal striatum): exposure effect (F1,51=41.6, p<0.01); 
5-HT (dorsal striatum): genotype × exposure effect (F2,51=4.85, p<0.05). 
 
 
3. Paper III 
3.1. Elevated plus-maze 
There was no difference in the basal exploratory activity between genotypes. It 
was found that in homozygous Wfs1-deficient mice, ethanol induced a signi-
ficant increase in open arm exploratory behavior (Figure 13).  
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Figure 13. The effect of ethanol (0.5–2.0 g/kg) on the exploratory behavior of Wfs1-
deficient mice in the elevated plus-maze test. n=7–8 per group. ** – p<0.01 compared 
to vehicle-treated homozygous mice; + – p<0.01 compared to homozygous mice treated 
with ethanol at a dose of 2 g/kg; @ – p<0.05 compared to wild-type mice treated with 
ethanol at a dose of 2 kg/kg. WT – wild-type mice, HET – heterozygous mice, KO – 
homozygous mice. 
 
3.2. Motor coordination in the rotarod test 
3.2.1. Latency to the first fall from the drum 
There was a significant effect of trial (F2,88=9.2, p<0.01), but not genotype 
(F2,44=0.1, p=0.86) and trial × genotype (F4,88=1.6, p=0.16). Wfs1-deficient 
mice showed substantial improvement in motor skill performance over trials as 
they displayed longer latency to fall from the rotarod on the third trial compared 
to the first trial (Figure 14A). In wild-type and heterozygous mice, no 
remarkable change in this parameter was seen over trials.  
A significant effect of ethanol treatment (F1,44=35,3, p<0.01), but not geno-
type (F2,44=1.7, p=0.17) or genotype × treatment (F2,44=0.02, p=0.98) was 
demonstrated. Treatment with ethanol (2 g/kg) significantly decreased the latency 
to fall from the rotarod in all the genotypes (Figure 14C). 
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Figure 14. The effect of trial (A, B) and ethanol (2.0 g/kg) (C, D) on motor coordi-
nation of Wfs1-deficient mice in the rotarod test. n=7–8 per group. # – p<0.01 
compared to the first measurement in homozygous mice; and – p<0.05 compared to the 
third measurement in wild-type mice; ** – p<0.01, * – p<0.05 compared to the respective 
vehicle-treated group. WT – wild-type mice, HET – heterozygous mice, KO – homo-
zygous mice. 
 
3.2.2. The number of falls 
Again, there was a significant effect of trial (F2,88=9.5, p<0.01), but not 
genotype (F2,44=0.7, p=0.52) and trial × genotype (F4,88=1.0, p=0.39). Wfs1-
deficient mice showed a 
gradual decrease in the number of falls over trials, but this change did not 
reach the level of statistically significant difference (Figure 14B). In hetero-
zygous mice, no significant improvement in performance was detected over 
trials. Wild-type mice fell substantially less on the third trial compared to their 
second trial due to the high number of falls on the second trial (p<0.05) (Figure 
14B).  
There was a significant effect of ethanol treatment (F1,44=21.4, p<0.01), but 
no genotype (F2,44=1.7, p=0.20) or genotype × treatment (F2,44=0.5, p=0.61) 
effects. Treatment with ethanol (2 g/kg) caused less incoordination in Wfs1-
deficient mice as it failed to induce significant increase in the number of falls 
from the drum (Figure 14D). 
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3.3. Loss of righting reflex (LORR) 
3.3.1. Ethanol 
One-way ANOVA revealed a significant genotype effect for both onset of 
LORR (F2,19=11.9, p<0.01) and duration of LORR (F2,19=3.4, p<0.05). In 
Wfs1-deficient mice, ethanol (4 g/kg) significantly increased both the latency to 
LORR and the duration of LORR as compared to wild-type mice (Figure 15A). 
Compared to ethanol-treated heterozygous mice, homozygous mice also 
demonstrated a longer latency to LORR. 
 
Figure 15. The onset and duration of loss of righting reflex (LORR) in Wfs1-
deficient mice after administration of ethanol (4.0 g/kg) (A), pentobarbital (45 
mg/kg) (B) and ketamine (150 mg/kg) (C). n=7–8 per group.** – p<0.01; * – p<0.05 
compared to wild-type mice; and – p<0.01 compared to heterozygous mice. WT – wild-
type mice, HET – heterozygous mice, KO – homozygous mice. 
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3.3.2. Pentobarbital 
There was a significant genotype effect for the duration of LORR (F2,19=4.1, 
p<0.05), but not for the onset of LORR (F2,19=1.9, p=0.16). Post-hoc com-
parison revealed that pentobarbital (45 mg/ kg) induced a similar onset of 
LORR in all genotypes. As for the duration of LORR, Wfs1-deficient mice 
treated with this GABAA agonist slept significantly longer compared to wild-
type animals (Figure 15B). 
 
3.3.3. Ketamine 
One-way ANOVA established a significant genotype effect for the onset of 
LORR (F2,19=7.9, p<0.01), but not for the duration of LORR (F2,15=0.04, 
p=0.96). In Wfs1-deficient mice, ketamine (150 mg/kg) significantly delayed the 
latency to LORR compared to wild-type mice (Figure 15C). In heterozygous 
mice, ketamine increased the latency to LORR compared to wild-type mice. No 
remarkable differences in the duration of LORR were established between the 
genotypes. 
 
3.4. Gene expression studies 
Two-way ANOVA did not establish any significant effects for Gabra1 and 
Gabra3 genes (data not shown). Post-hoc analysis revealed that 60 min after the 
injection ethanol-treated homozygous mice displayed a remarkable increase in 
the levels of Gabra2 in the temporal lobe as compared to the Wfs1-deficient 
vehicle group (Figure 16A). Two-way ANOVA established a significant effect 
of ethanol treatment (F2,39=6.9, p<0.01), but not genotype (F1,39=0.2, p=0.64) 
and genotype × ethanol treatment (F2,39=0.96, p=0.39). 
In the frontal cortex, homozygous mice had remarkably higher levels of 
Gabra2 mRNA 30 min after ethanol injection compared to the respective group 
of wild-type mice (p<0.01) (Figure 16B). However, at 60 min post injection of 
ethanol, the levels of Gabra2 in homozygous mice had returned to the level of 
vehicle-treated mice. With two-way ANOVA we found significant effects of 
ethanol treatment (F2,39=4.9, p<0.01) and genotype × ethanol treatment 
(F2,39=3.8, p<0.05), but not genotype (F2,39=2.7, p=0.10).  
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Figure 16. The effect of acute ethanol administration after 30 or 60 min on the 
expression of Gabra2 subunit of GABAA receptor in the temporal lobe (A) and 
frontal cortex (B). n=6–8 per group. * – p<0.05 compared to vehicle-treated homo-
zygous mice; # – p<0.01 compared to ethanol 30 min group of homozygous mice; and – 
p<0.05 compared to vehicle-treated homozygous mice. & – p < 0.05 compared to 
vehicle-treated homozygous mice WT – wild-type mice, HET – heterozygous mice, KO – 
homozygous mice. 
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DISCUSSION 
WS patients and people with mutations in the WFS1 gene exhibit a higher 
incidence of mood disorders with comorbid anxiety. We have in the three 
articles comprising the dissertation studied the possibility that Wfs1 deficiency 
in mice induces behavioral symptoms reflective of the human neuropsychiatric 
states and biochemical alterations to associated brain systems. Therefore, in the 
first and second articles, we sought to measure the behavioral and biochemical 
response of Wfs1-deficient mice to DA-ergic, 5-HT-ergic and NA-ergic agonists. 
In the third article, the anxiety of Wfs1-deficient mice was studied with an 
emphasis on the central GABA system, targeted by anxiolytic drugs. Although 
in humans, carriers (heterozygotes) have increased susceptibility to psychiatric 
diseases, the effect of Wfs1 heterozygosity in mice was not clearly evident in 
the studies. Therefore, only the results from homozygous Wfs1-deficient mice 
are discussed in relation to wild-type animals.  
 
 
1. Dopamine 
There was a tendency for lower basal locomotor activity in Wfs1-deficient 
homozygous mice but this difference was statistically non-significant. Exposure 
of vehicle-treated mice to the automated motility boxes revealed a significantly 
stronger increase in the tissue level of homovanillic acid (HVA), a major meta-
bolite of DA, both in the dorsal and ventral striatum of wild-type and Wfs1-
deficient heterozygous mice compared to their homozygous littermates. This 
change is likely related to increased DA utilization in wild-type and hetero-
zygous animals under the influence of motility box exposure and could reflect 
the moderately lower activity of homozygous mice compared to the other 
genotypes.  
As shown before (Luuk et al., 2009), homozygous Wfs1-deficient mice had 
significantly lower locomotor activity in response to the acute administration of 
amphetamine and we found this phenotype to persist even with repetitive 
administrations of a subthreshold dose (2.5 mg/kg) of amphetamine. Ampheta-
mine (5 mg/kg) significantly increased tissue levels of DA in the dorsal and 
ventral striatum of wild-type mice, but not in their homozygous littermates. The 
influence of amphetamine on DA turnover was significantly reduced in the 
dorsal and ventral striatum of homozygous animals compared to other geno-
types. It is known that the administration of DA agonists reduces turnover of 
DA as a homeostatic mechanism (Bannon et al., 1980). Although the tissue 
monoamine content measurement by HPLC does not directly reflect DA 
release, it is reasonable to speculate that DA release is impaired since ampheta-
mine is a substrate for the DA transporter (DAT), which reverses DAT to 
release DA from the presynaptic neurons and thereby increases locomotor 
activity (Jones et al., 1998). By default, DAT is responsible for clearing DA 
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from the synaptic cleft (Sulzer et al., 2005). In support to this, Matto et al 
(2011) have showed blunted potassium-induced release of striatal DA in 
homozygous Wfs1-deficient mice (Matto et al., 2011). We next measured DAT 
levels in order to clarify the reasons for reduced potency of amphetamine in 
Wfs1-deficient mice. The gene expression measurements revealed marked 
differences between genotypes. In both sexes, the expression level of the DAT 
gene was significantly reduced in the ventral midbrain of homozygous mice 
compared to wild-type animals. We aimed to substantiate gene expression 
findings with protein analyses. Although there were no significant statistical 
differences between genotypes, the level of DAT protein remained lower in the 
dorsal striatum of male and female homozygous mice compared to wild-type 
animals. This was not reflected in the ventral striatum.  
To test the intactness of the DA receptors, we injected apomorphine (3 mg/kg), 
which caused a significant motor stimulation in heterozygous and homozygous 
Wfs1-deficient mice, but not in wild-type animals. Apomorphine is a non-
selective DA agonist that directly stimulates the DA D1 and D2 receptors, 
having more preference for the D2 receptors (Millan et al., 2002). Treatment 
with apomorphine caused a similar reduction of DA utilization across all 
genotypes. The expression of Drd2 gene (gene for DA D2 receptor) was not 
affected in the ventral striatum of male and female Wfs1-deficient animals. In 
the dorsal striatum of male Wfs1-deficient mice the expression of Drd2 gene 
was reduced but in female homozygous mice it remained unchanged. The data 
thus indicate that the disruption of Wfs1 gene does not affect the regulation of 
DA signaling via DA D1 receptors. In the literature, this claim receives support 
as the D1 receptors are also considered to be responsible for mediating locomotor 
activity (Xu et al 1994). 
According to the clinical studies a significant number of WS patients suffer 
from depression (Swift et al, 1990). It is generally accepted that 5-HT and NA 
play a role in the etiology and treatment of depression (Delgado et al., 1990, 
Neumeister et al., 2004, Moret & Briley, 2011). However, it has become 
apparent that DA in the striatum, involved in the neural circuits of movement, 
motivations and reward, plays a distinct role in the neurobiology of depression 
(Dailly et al., 2004, Salamone et al., 2012). The role of DA in depression is 
evident in Parkinson’s disease patients who reportedly have a 40% higher risk 
of depression (Cummings, 1992). Taking into account the role of DA in 
depression, it can be hypothesized that the impaired function of DA-ergic 
system established in Wfs1-deficient mice might be extended to WS patients in 
order to help explain their depressive symptoms. 
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2. Serotonin and noradrenaline 
The 5-HT-ergic and NA-ergic monoamine systems have classically been 
associated with mood disorders. In the second article we studied whether there 
are alterations in the 5-HT-ergic and NA-ergic systems owing to Wfs1 deficiency. 
The behavioral despair paradigm has been used for modeling depression-like 
behavior in rodents and encompasses two behavioral experiments, the tail 
suspension test (TST) and forced swim test (FST), both of which show 
sensitivity to antidepressant drugs. We utilized two different kinds of anti-
depressants, the selective serotonin reuptake inhibitor (SSRI) paroxetine and 
tricyclic antidepressant (TCA) imipramine. Paroxetine exerts its effect by 
blocking the 5-HT transporter (SERT) and imipramine blocks, in addition to 
SERT, also the NA transporter (NAT). These two transporters are similar in 
function to the DAT, which clears excess DA from the synaptic cleft. By 
blocking SERT and NAT, more 5-HT and NA will be left in the cleft, thereby 
mediating an antidepressant-like behavioral effect in rodents. This means that 
mice, who have been administered an antidepressant, will spend less time 
immobile while suspended from their tails or swimming. Statistical comparison 
of basal immobility times did not show significant differences between the three 
genotypes in either of the two tests. Similarly, Kato et al 2008, using a different 
model of Wfs1-deficient mice, did also not report marked deviations in the 
basal activity levels in the TST and FST (Kato et al., 2008). Our results 
demonstrate that the doses of paroxetine and imipramine, necessary for 
significantly reducing immobility time compared to drug-naive animals of the 
same genotype, are lower in homozygous mice than in their wild-type 
littermates. The effectiveness of paroxetine was higher than that of imipramine, 
thus one could suggest that SERT has a more prominent role in the elevated 
behavioral response of homozygous mice. Next, we measured gene expression 
levels of SERT and NAT in experimentally naïve mice. Homozygous mice 
exhibited significantly lower expression of SERT mRNA in the pons as 
compared to their wild-type littermates. Moreover, the expressions of SERT in 
the midbrain and NAT in the pons tended to be lower, but these differences 
were not statistically significant. Based on these findings, it can be speculated 
that the activity of SERT, but not NAT, is lower in Wfs1-deficient mice which 
may contribute to altered response to imipramine and paroxetine in these mice. 
Further studies measuring SERT and NAT protein expression need to be done 
to confirm these changes in Wfs1-deficient mice. 
The following step was to evaluate the effect of a stressful (brightly lit) 
motility box challenge on the metabolism of 5-HT and NA in the dorsal and 
ventral striatum as a large body of research have shown that 5-HT in different 
brain areas might provide adaptation to stress (Chaouloff et al., 1999). Stress 
induces elevated levels of the 5-HT in the hypothalamus (Shimizu et al, 1992) 
and elevates 5-HT metabolism in the nucleus accumbens, medial prefrontal 
cortex and amygdala (Inoue et al., 1994). In addition, 5-HT-ergic pathways 
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innervate the striatum (Sur et al., 1996) and stress can have a robust effect by 
increasing 5-HT levels in the striatum (Kirby et al., 1995). Exposure to a 
brightly lit environment induced notable changes to the levels of 5-HIAA, a 
metabolite of 5-HT. A statistically significant elevation of 5-HIAA levels was 
established in the dorsal and ventral striatum of heterozygous and wild-type 
mice. However, in the homozygous mice, the elevation of 5-HIAA was blunted. 
By contrast, we did not find any changes in the levels of NMN, a metabolite of 
NA, demonstrating a stronger role of 5-HT in the stress coping mechanism of 
mice. In stress-challenged wild-type mice, the levels of 5-HT tended to be 
elevated in the dorsal striatum but this effect was statistically significant only in 
the ventral striatum. 5-HT levels did not significantly change in Wfs1-deficient 
animals. Therefore, the present study reveals stronger activation of 5-HT system 
in wild-type mice compared to Wfs1-deficient mice. Moreover, this finding, 
together with the reduced expression of SERT, can be indicative of the 
compromised function of 5-HT system and stress response in animals lacking 
the Wfs1 gene. 
 
 
3. GABA 
In the third article, the GABA-ergic phenotype of Wfs1-deficient mice was 
studied. To test if GABAA-receptor (GABAA-R) is affected we administered 
ethanol, a GABAA-R agonist. It was found that the anxiolytic-like effect of 
ethanol was increased in Wfs1-deficient homozygous mice since they displayed 
lower levels of behaviors associated with anxiety in the elevated plus maze 
(EPM) test. Ethanol did not induce any significant anxiolytic-like effects in 
wild-type and heterozygous mice. Anxiety-related effect of ethanol was 
distinguished from its locomotor-enhancing properties by observing that it did 
not cause a significant increase in horizontal activity in the motility box test. All 
the genotypes had similar blood ethanol kinetics following the administration of 
ethanol (2 or 4 g/kg) (data not shown). It can therefore be excluded the effect of 
ethanol on activity behavior was caused by altered ethanol metabolism. We had 
previously found a similar behavioral response in Wfs1-deficient to diazepam, 
also a GABAA-R agonist, confirming the present pharmacological findings 
(Luuk et al 2009). 
In the rotarod test, ethanol (2 g/kg) impaired motor coordination in all 
genotypes, however, impairment of performance was less obvious in Wfs1-
deficient mice since ethanol failed to induce a substantial increase in the 
number of falls from the rotarod in these mice. The results suggest that Wfs1 
deficiency decreases sensitivity to the sedative/ataxic effect of ethanol. Loss of 
righting reflex (LORR) test revealed genotype differences in the sedative 
response to ethanol as the onset of LORR was delayed in Wfs1-deficient mice. 
At the same time, a significant increase in the duration of LORR seen in mice 
lacking Wfs1 gene points to a stronger hypnotic effect of ethanol in these mice. 
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In the case of pentobarbital (45mg/kg), a GABAA-R modulator, all the geno-
types demonstrated a similar onset of LORR, whereas Wfs1-deficient mice slept 
for a longer time than wild-type mice. Ketamine, an antagonist of NMDA 
receptors, increased the latency of LORR in Wfs1-deficient mice, but did not 
cause significant differences in the duration of LORR between the genotypes. 
These results indicate that decreased sensitivity to the sedative effect of ethanol 
in mice lacking Wfs1 gene may be related to the altered function of both 
GABAA and NMDA receptors. At the same time enhanced sensitivity to the 
hypnotic effect of ethanol in mice lacking Wfs1 gene is related to the altered 
function of GABAA receptor rather than NMDA receptors. 
It has been suggested that among the subunits of GABAA-Rs, the α2 
(Gabra2) subunit might be responsible for the hypnotic action of ethanol 
because mice lacking the α2 gene display shorter ethanol-induced LORR (Boehm 
et al., 2004). The exact brain region responsible for the regulation of ethanol-
induced LORR is not clearly known, but because temporal lobe structures (eg 
amygdala and entorhinal cortex) regulate sleep-wake cycle (Leung et al., 2014), 
one may expect that changes there could reflect mediating mechanisms for 
ethanol-induced LORR. 
Gene expression studies revealed that the anxiolytic dose of ethanol (2 g/kg) 
had no effect on the levels of Gabra1 and Gabra3 mRNA following ethanol 
treatment. At the same time, a significant increase in Gabra2 mRNA was 
detected in the frontal cortex of Wfs1-deficient mice at 30 min after ethanol 
injection as compared to the respective vehicle-treated mice. Comparison of 
ethanol exposed groups at 30 min after ethanol injection showed that Wfs1-
deficient mice displayed significantly higher levels of Gabra2 mRNA than wild-
type mice. The temporal lobe displayed the same dynamic of Gabra2 gene 
expression 60 min after ethanol treatment as was seen in the frontal cortex. 
Differences in ethanol responsive gene expression networks may contribute to 
altered ethanol-induced behavioral phenotype in Wfs1-deficient mice. Both 
brain areas used in the gene expression studies are relevant for the regulation of 
negative emotions, including anxiety (Martijena et al., 2002, Panksepp, 1998, 
Leistedt & Linkowski, 2013). Therefore, the increased level of Gabra2 mRNA 
following ethanol treatment in these brain areas may explain the increased 
sensitivity to anti-anxiety effect of ethanol in Wfs1-deficient mice. 
Results from human research also appear to support the finding that Gabra2 
gene mediates the stimulating effect of ethanol. Several genetic studies have 
shown the involvement of GABRA2 in increased stimulation and euphoria 
following ethanol administration (Arias et al., 2014) and in the pathogenesis of 
alcohol dependence (Uhart et al., 2013, Arias et al., 2014, Li et al., 2014). On 
the other hand transgenic mice lacking the Gabra2 subunit displayed a tendency 
for increased exploratory activity in response to ethanol administration 
indicating that the Gabra2 subunit is not required for anti-anxiety effect of ethanol 
(Boehm et al., 2004). Moreover, it cannot be entirely excluded that the increased 
anxiolytic effect of ethanol is also mediated by alterations in the 5-HT-ergic 
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system, which is also targeted by ethanol and has been shown to be affected in 
homozygous Wfs1-deficient mice (Paper II). 
In mice, the magnitude of anxiogenic effect of alcohol depends on many 
factors, such as the genetic background, the dose of ethanol and the nature of the 
behavioral task (Durcan & Lister, 1988, Cao et al., 1993, Stewart et al., 1993). 
Differences in mouse background used for producing transgenic animals most 
likely explain discrepancies between these and our studies. Indeed, it has been 
established that 129 substrains have extensive genetic variability (Simpson et 
al., 1997) and, therefore, the different substrains may not be equally sensitive to 
all effects of ethanol. It should be noted that only female mice were used in the 
current study. Sex differences in anxiety behavior following acute ethanol 
administration have been reported before (Abramov et al., 2006). 
Finally, it has to be taken into account that the monoamines share a complex 
reciprocal relationship with GABA (Brambilla et al., 2003). Administering 
GABA agonists or GABA transaminase inhibitors results in reduced DA neuron 
firing and D2 receptor binding (Dewey et al. 1992, Schiffer et al., 2000). Also, 
GABA agonists tend to reduce 5-HT synthesis (Nishikawa & Scatton, 1983, 
Nishikawa & Scatton, 1985). On the other hand, some studies find that GABA 
agonists can probably also stimulate the DA- and 5-HT-ergic systems, depending 
on different experimental applications (Garbutt & van Kammen, 1983, 
Francois-Bellan et al., 1988). Similarly, depending on the type of manipulation 
to the monoaminergic system, GABA levels can be elevated or lowered 
(Harsing & Zigmond, 1997, Seamans et al., 2001). Together, the relationship 
between monoamines and GABA would need to be elucidated further in Wfs1-
deficient animals to ascertain the precise alterations to the interplay of these 
neurotransmitter systems. 
 
 
4. Concluding remarks and future prospects 
This dissertation is based on studies conducted on the monoaminergic and 
GABA-ergic systems of Wfs1-deficient mice. These systems are strongly 
implicated in the etiologies of mood and anxiety disorders and therefore also 
targeted by drugs used in the treatment of depression and anxiety. 
Mice deficient in Wfs1 are less sensitive to the locomotion-enhancing 
effects of indirect DA agonist amphetamine and more sensitive to the post-
synaptic DA agonist apomorphine. Moreover, the release and metabolism of 
DA is altered. In general, the DA-ergic system seems to be impaired in Wfs1-
deficient mice. Although these findings are apparent when comparing Wfs1-
deficient and wild-type animals, other causes that result in similar DA system 
alterations and behavioral phenotype, such as insulin or calcium levels, have 
been identified in the past. The behavioral phenotype we have observed in 
Wfs1-deficient animals only partly mimics that of insulin deficient animals. 
Further experiments (for example with insulin replacement) would need to be 
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performed to confirm whether this impairment is caused by the insulin 
deficiency that inevitably accompanies Wfs1 deficiency and has been shown to 
disrupt the DA-ergic system in diabetic animal models. In addition, it is 
necessary to conduct experiments to measure and manipulate calcium levels in 
the brains of Wfs1-deficient animals to ascertain the true role of Wfs1 
deficiency in the impaired DA-ergic phenotype. 
Wfs1 deficiency produces distinct changes to the 5-HT-ergic system. We did 
not see any notable effects of Wfs1 deficiency on the NA-ergic system. There 
were no differences to the baseline levels of immobility parameters in the 
behavioral despair tests, therefore these animals cannot be considered 
“depressed”. Instead, Wfs1-deficient homozygous mice are more sensitive to 
SSRI and TCA drugs paroxetine and imipramine in the behavioral despair tests 
and this phenotype makes them suitable for studying both classes of anti-
depressants. The other method we employed here was a stressful environment 
which normally causes an elevation of 5-HT levels in various emotion- and 
stress-related areas. The levels of striatal 5-HT were blunted or even lower in 
exposed Wfs1-deficient animals which could be interpreted as an indicator of a 
disturbed molecular coping mechanism.  
It has been observed previously that Wfs1-deficient animals are more anxious 
and responsive to the GABAA receptor agonist diazepam which is a highly 
effective anxiolytic drug. In addition, some of the Wfs1-deficient animals have 
consistently displayed characteristic vocalizations under stress. Here, the 
animals were more responsive to ethanol in the elevated plus maze. It is likely 
that the behavioral anxiety phenotype was not observed because of different 
experimental conditions. This discrepancy warrants further clarification. The 
fact that Wfs1-deficient mice are behaviorally more sensitive to both GABA 
receptor agonists would make them candidates for anxiolytic screening. 
Altogether, these results indicate this to be a mouse model that has bio-
chemical alterations in brain systems implicated in mediating movements, 
emotions and anxiety. These Wfs1-deficient mice could be considered a 
potentially useful model for the screening of antidepressants and anxiolytics. 
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CONCLUSIONS  
In the three articles we studied the possibility that Wfs1 deficiency in mice 
induces behavioral symptoms reflective of human psychiatric states and 
alterations to central DA-ergic, 5-HT-ergic, NA-ergic and GABA-ergic systems. 
 
Dopamine 
1. In the first article, we found that Wfs1-deficient mice have altered behavioral 
responses to DA agonists and biochemical impairments in the DA-ergic 
system. The presynaptically acting drug amphetamine had a lower 
locomotion-inducing effect in these animals, both when given acutely and 
chronically. Apomorphine, which is a direct DA receptor agonist, induced a 
higher behavioral response in Wfs1-deficient mice. 
2. It was found that DA levels did not rise in response to amphetamine 
administration and the turnover of DA was not inhibited in Wfs1-deficient 
animals. On the other hand, apomorphine caused a significant reduction in 
DA turnover across the genotypes.  
In summary, DA metabolism was affected by Wfs1-deficiency and this 
might be a cue about the causes of emotional disorders seen with WFS1 
mutations in humans. 
 
Serotonin and noradrenaline 
1. In the second article we found that Wfs1-deficient animals have altered 
response to antidepressant drugs in behavioral despair tests and a blunted 5-
HT reaction in a stressful environment. The animals did not have baseline 
differences in the time spent immobile in the TST or spent swimming (FST). 
By contrast, Wfs1-deficient mice had a heightened response to antidepressants 
in both behavioral despair tests. The SSRI antidepressant paroxetine was 
more effective at a lower dose than the TCA imipramine, possibly reflecting 
a stronger 5-HT-ergic alteration in homozygous Wfs1-deficient animals. 
2. Further, we subjected Wfs1-deficient animals and their wild-type littermates 
to a stressful open field environment to measure the biochemical response of 
the mice. Stressful conditions are known to cause elevation in central 5-HT 
levels. We found that 5-HT levels did not rise in response to this experi-
mental manipulation in Wfs1-deficient mice. Differently from Wfs1-
deficient animals, this rise was detected in wild-type mice.    
It can therefore be concluded that the adaptation to stress might be impaired 
in Wfs1-deficient animals due to 5-HT-ergic alterations. 
 
Gamma-aminobutyric acid 
1. In the third article, it became evident that Wfs1-deficient mice were more 
responsive than wild-type animals to ethanol in the elevated plus maze test and 
also found GABAA receptor subtype expression differences. Intriguingly, the 
baseline levels of anxiety were not different between the genotypes. 
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2. Because GABAA-R is known to mediate ethanol-induced anxiolytic effect, 
we measured the gene expression levels of GABAA-R subtypes in Wfs1-
deficient animals. Ethanol upregulated the expression of GABAA subtype α2 
encoding gene Gabra2. This subtype of GABAA receptor has been 
implicated in mediating the anxiolytic effect of GABAA agonists. The study 
suggests that both anxiolytic-like and sedative/hypnotic properties of ethanol 
are changed in Wfs1-deficient mice. The increased level of Gabra2 mRNA 
expression after ethanol administration in brain areas considered responsible 
for experiencing anxiety could partly explain the greater anxiolytic-like 
effect of ethanol. 
 
In general, Wfs1 deficency induces distinct changes to the DA-ergic, 5-HT-
ergic and GABA-ergic systems. We did not detect notable changes to the NA-
ergic system. Taken together, the results of the pharmacological studies show 
that this Wfs1-deficient mouse model is a potentially viable option for 
translational medicine in the field of anxiolytic and antidepressant screening 
and to test new drug administration schemes in the treatment of WS. 
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EESTI-KEELNE KOKKUVÕTE 
Wfs1 geeni puudulikkusega hiire monoamiinergilise ja  
GABA-ergilise süsteemi farmakoloogiline ja  
käitumuslik iseloomustus 
WFS1 geenilt toodetakse volframiini (WFS1 valk). Homosügootsed mutatsioo-
nid ja mõned liitheterosügootsuse variandid WFS1 geenis põhjustavad väga 
haruldast ja rasket Wolframi sündroomi (WS), mida iseloomustavad suhkur-
diabeedi, magediabeedi, optilise närvi atroofia ja kurtuse esinemine. WS pat-
sientidel ja WFS1 heterosügootidel, kel WS-i pole, esineb sageli psühhiaatrilisi 
häireid nagu depressioon ja ärevus. Lisaks on teatud WFS1 geeni polü-
morfismid seotud psühhiaatriliste häiretega. Kuigi WFS1 geeni puudulikkus on 
seotud psühhiaatriliste sümptomitega, pole teada, millised muutused ajus sel 
puhul tekivad. Samuti on volframiini täpne ekspressioon teada ainult hiire ajus. 
Volframiin lokaliseerub ajus piirkondades, mis on olulised tunnete, hirmu ja 
käitumise regulatsioonis (mh amügdalas, hipokampuses, dorsaalses ja ventraalses 
striaatumis ning stria terminalise sängituumas). Uurimaks volframiini puudu-
likkusest tulenevaid käitumuslikke ja biokeemilisi muutusi, loodi Wfs1-
puudulik hiireliin. Esialgsed uuringud näitasid, et see hiireliin on metsiktüüpi 
hiirtega võrreldes oluliselt ärevam ja tal võib esineda kõrvalekaldeid dopamiin-
ergilise ja gamma-aminovõihappe (GABA) süsteemi töös. 
Käesolevas töös uurisime laiemalt, kui suurel määral Wfs1-puudulike hiirte 
käitumuslik fenotüüp sarnaneb WSF1 mutatsioonidest tulenevatele psühhiaatri-
listele nähtudele ja millised muutused esinevad neil aju monoamiinergilistes 
(dopamiin, serotoniin, noradrenaliin) ja GABA süsteemides. Tsentraalsed 
monoamiinid on olulised käitumise ja meeleolu regulatsioonis. GABA on 
peamine inhibitoorne neurotransmitter ajus, ja GABAA retseptorid omavad 
olulist rolli ärevushäirete ravis, olles anksiolüütikumide sihtmärgiks. 
Esimeses artiklis uurisime dopamiinergilise süsteemi kõrvalekaldeid. Leid-
sime, et Wfs1-puudulike homosügootsete hiirte reaktsioon kaudse dopamiini 
agonistina toimiva amfetamiini käitumuslikku aktiivsust tõstvale toimele on 
oluliselt väiksem kui metsiktüüpi hiirtel. Teisalt on Wfs1-puudulikud hiired 
käitumuslikult tundlikumad apomorfiinile, mis võib olla dopamiini retseptorite 
ülesregulatsioonist tulenev, sest see ravim toimib dopamiiniretseptori otsesese 
agonistina. Lisaks, amfetamiini manustamine tõstis dopamiini tasemeid metsik-
tüüpi ja heterosügootsete loomade striaatumis, kuid olulist tõusu ei esinenud 
Wfs1 homosügootsetel hiirtel. Peale selle oli amfetamiini mõju dopamiini 
ringkäigule Wfs1-puudulikel hiirtel erinev metsiktüüpi hiirtest. Wfs1-puudu-
likel hiirtel esines ventraalses keskajus dopamiini transporterit (DAT) kodeeriva 
geeni oluliselt madalam ekspressioon. Kuigi geeniekspressioonilt oli DAT 
madalam, ei leidnud me sellele erinevusele kinnitust striaatumis valgu-
ekspressiooni kujul. 
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Teises artiklis vaatlesime serotonergiliste ja noradrenergiliste süsteemide 
muutusi Wfs1-puudulikes hiirtes, kasutades närilistele stressitekitavalt mõjuvat 
avarväljakatset ja nö käitumusliku ahastuse loomkatsemudeleid – sabast riputa-
mise ning sunnitud ujumise katseid. Käitumuslik ahastus peegeldab looma 
akuutset „depressiooni” ja on üldiselt tundlik antidepressantide manustamisele. 
Sabast riputamise ja sunnitud ujumise katseid kasutatakse meeleoluhäirete ravis 
oluliste ravimite skriinimiseks. Käitumusliku ahastuse katsetes kasutasime 
selektiivset serotoniini tagasihaarde inhibiitorit paroksetiini ja tritsüklilist anti-
depressanti imipramiini, mis mõjub noradrenaliini transporteri inhibiitorina. 
Wfs1-puudulikel hiirtel esines suurem tundlikkus nende ravimite võimele 
vähendada liikumatust, kusjuures käitumuslikult tugevamalt mõjusid pigem 
väiksed paroksetiini doosid. Avarväljale eksponeerimine tõi esile pigem 
serotonergilised muutused Wfs1-puudulikel homosügootsetel hiirtel: serotoniini 
tase ei tõusnud Wfs1-puudulikel hiirtel striaatumis vastusena stressitekitavasse 
keskkonda paigutamisele (dorsaalses striaatumis esines isegi langus). Samas 
esines serotoniini taseme tõus metsiktüüpi hiirtel. Need tulemused peegeldavad 
stressile adapteerumisel olulise neurotransmittersüsteemi kõrvalekallet 
tulenevalt Wfs1 puudulikkusest. 
Kolmandas artiklis keskendusime Wfs1-puudulike hiirte ärevusfenotüübi ja 
gamma-aminovõihappe (GABA) süsteemide uurimisele. Ilmnes, et etanoolil oli 
Wfs1-puudulikele hiirtele suurem anksiolüütiline toime ülestõstetud pluss-
puuris. Etanool ei halvendanud rotarod testis homosügootsetel Wfs1-puudulikel 
hiirtel motoorset koordinatsiooni samaväärselt teiste genotüüpidega, mistõttu 
võib järeldada, et Wfs1 puudulikkus vähendab tundlikkust etanooli sedatiivsele 
ja ataksilisele mõjule. Nn püstumise kadumise testis (Loss of righting reflex, 
LORR) oli LORRi algus Wfs1-puudulikel hiirtel hilisem peale etanooli 
manustamist. Samal ajal oli LORRi kestvus pikem, mis peegeldab etanooli 
suurenenud hüpnootitilist efekti neis hiirtes. LORRi algus oli peale pentobarbi-
taali (GABAA modulaator) manustamist kõigil genotüüpidel sarnane, kuid 
kestvus oli jällegi Wfs1-puudulikel hiirtel pikem. Ketamiini (NMDA anta-
gonist) manustamise järgselt polnud genotüüpide vahelisi erinevusi LORRi 
kestvuses. Lisaks sellele tõusis nende hiirte GABAA retseptori α2 alaühikut 
kodeeriva geeni Gabra2 ekspressioon vastusena etanooli manustamisele. 
GABAA retseptori α2 alaühikut peetakse oluliseks anksiolüütikumide toime 
vahendamises.  
Kokkuvõtvalt uurisime Wfs1-puudulikel hiirtel monoamiinergilist ja GABA-
ergilist fenotüüpi. Tulemused näitavad, et kõigis neis süsteemides (va noradre-
nergilises) on kõrvalekaldeid ja need võivad peegeldada WFS1 mutatsioonidega 
inimeste neuropsühhiaatriliste häirete põhjuseid. Käitumuslikult on see hiireliin 
ärevam ja samas tundlikum ärevus- ja meeleoluhäirete raviks kasutatavatele 
ravimitele. See Wfs1-puudulik loommudel omab potentsiaali olla olulise tähtsu-
sega siirdemeditsiinilistes uuringutes, et tuvastada efektiivsemad ravimid ja 
raviskeemid WS-ga kaasnevate häirete ravis. 
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